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1 Review of the Literature 
1.1 Introduction 
Biomedical sciences have in the recent years taken great leaps forward in the 
understanding of human genetics, gene expression regulation and studies of human 
cancer. The development is in many ways linked to the advances made in the electronic 
industry and information technology, which have been successfully applied to the 
biological sciences. This has created new technologies and automated methods, such as 
microarray technology. Microarrays cover a broad range of applications ranging from 
genetic research and molecular biology related analysis to pharmacogenomic and 
forensic purposes. The focus of this dissertation is the expression microarray 
technology and its use in cancer research, and the following chapters will hence be 
limited to these subjects. 
1.2 Genes and gene expression 
The genetic material of most living organisms is known as deoxyribonucleic acid 
(DNA). DNA is composed of nucleotides containing a sugar-phosphate backbone and 
attached bases. There are four different bases: adenine (A), cytosine (C), guanine (G) 
and thymine (T). The bases bind to each other in a complementary manner; A to T and 
C to G, respectively, using hydrogen bonding. The sugar phosphate backbones of the 
nucleotides bind covalently to each other and form long chains of nucleotides. A DNA 
molecule consists of two complementary polynucleotide chains held together by the 
base-pair binding, hydrophobic effects and pi-stacking and form a right-handed double 
helix structure, which is typically millions of nucleotides in length. As the nucleotides 
are joined in an ordered fashion with the 3’ hydroxyl group binding to the 5’ hydroxyl 
group of the previous nucleotide, the two strands of the helix become polarized and are 
in an antiparallel orientation to each other with opposite 5' - 3' directions. The main 
purpose of DNA in a nucleus is to store information needed by the cell to function.[1-3] 
 
Another information-containing material that the cells utilize is ribonucleic acid 
(RNA), which is analogous to DNA but differs from it in several important ways. In 
RNA, the backbone sugar is ribose and uracil (U) has replaced T in the bases, and is 
now complementary to A. Unlike DNA, most RNA molecules are single-stranded and 
only 75-50000 nucleotides in length. Cells contain several types of RNA, of which 
messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA) are 
involved in the protein synthesis. 
 
Fuctional and physical units of heredity passed from parent to offspring are called 
genes. They are fragments of DNA, encompassing coding DNA sequences and introns, 
which in most cases contain the information for making a specific protein. Proteins are 
biologically active molecules produced by the cell and are responsible for the organized 
functioning of the cell. In essence, they control the physical traits that an organism has, 
such as eye, skin or hair color. Proteins are composed of sequences of twenty different 
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types of amino acids that, when linked together, are called polypeptides. Each amino 
acid is encoded by a sequence of three bases in the DNA called codons. Although there 
are 64 possible triplets, some redundancy exists and multiple codons code for the same 
amino acid. In addition, three codons have not been assigned to any amino acids but 
serve as termination signals for the synthesis.  
 
The process of synthesizing proteins is a two-step procedure that consists of 
transcription and translation, two processes collectively known as the central dogma of 
molecular biology. In the transcription step the information of the double-stranded 
DNA sequence is transferred into a single-stranded mRNA sequence. This is done by 
RNA polymerase, an enzyme that moves along one strand on DNA in 5’-3’ direction 
and produces a complementary sequence of mRNA. The DNA which is used to 
produce the RNA is called the antisense strand, while the complementary DNA is 
named the sense strand. The produced unmature mRNA strand is complementary to the 
antisense strand, and identical to the sense strand, with the exception of base T being 
changed to U. The transcription of a gene begins at regions of the DNA sequence 
known as promoter sites and ends at regions known as terminator sites. 
 
Translation, the second stage of the protein synthesis, is the process of constructing an 
amino acid sequence from a mRNA molecule. This is done by using ribosomes in the 
cytoplasm consisting of rRNA and proteins. In translation, the ribosomes use tRNA to 
attach to the mRNA and translate the bases into amino acids. tRNA molecules bring the 
specified amino acids to the translation site, where the ribosome links them together, 
forming an elongating chain of peptides. The translation starts from an AUG codon that 
marks the start of the peptide chain and terminates when a codon representing a stop 
signal is recognized. The formed polypeptide chain is then released from the translation 
site and modified into an active protein to serve its purpose in the cell. This process of 
converting DNA sequence into a protein is called gene expression. 
While the central dogma of molecular biology in principle still exists, the genetic and 
molecular interactions between nucleic acids and proteins have since then been 
discovered to compose of complex networks with multilateral signalling. 
Transcriptional and (post-)translational modifications, such as gene splicing, small 
RNAs and epigenetic methods such as methylation are examples of these processes.[4] 
 
The term genome is used to describe the total genetic information of an organism. Each 
cell of an organism contain identical genetic information, that is, DNA for every gene 
is present in all the cells of that organism. The human genome consists of roughly 3 
billion basepairs, and the current estimate of the total number of genes varies between 
20000 – 25000. While the genetic information of every cell is the same, the mRNA and 
protein levels vary between the cells. The number of genes expressed in a cell depends 
on the various environmental conditions the cells possess. In general, only a fraction of 
the genes (on average several thousands) are expressed simultaneously in any given 
cell type or tissue. Thus, gene expression studies are used to describe the levels of 
mRNA molecules produced in a collection of cells at a given time, which in general is 
proportional to the amount of protein and reflect the ongoing biological and functional 
processes of the cell. Traditionally gene expression studies have been done one gene at 
a time using technologies such as reverse-transcription polymerase chain reaction (RT-
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PCR) and northern blotting. Recently, the development of microarray technology has 
revolutionalized this concept. 
1.3 Expression microarray technology 
1.3.1 Introduction 
A DNA microarray is a miniature device containing cDNA fragments that are either 
synthesized directly or spotted onto glass or other matrix. Thousands of genes are 
represented in a single array, which is designed to simultaneously measure the 
expression levels of all these genes in a particular tissue or cell type. The basic concept 
of microarray technology is to hybridize preprocessed sequences of mRNA called 
targets to the complementary sequences called probes bound to a solid surface and to 
quantify the amount of specifically hybridized target, typically by fluorescence 
detection. Numerous technologies for this purpose have been developed, and these can 
be categorized based on the chip design, chemistry, manufacturing or signal detection. 
In general, microarrays are divided into complementary DNA (cDNA) arrays or 
oligonucleotide arrays based on the used probe material, in-situ synthesized or spotted 
(contact or non-contact) arrays based on the manufacturing method and one-color or 
two-color arrays based on the staining and detection technique. Other kinds of 
microarray systems, such as microelectronic arrays which use electrical fields to bind 
DNA to probes have also been developed,[5,6] but due to the limited scope of this 
dissertation these are not discussed further. Microarray technologies, applications and 
analysis methods have been extensively described in many reviews and books.[7-10] 
1.3.2 History of microarrays 
The roots of microarray technology can be found in the early biochemical “dot blot” 
experiments done in the 1970s, where DNA was immobilized on membranes and 
usually probed with radioactively labeled DNA or colorimetric assays.[11,12] The 
development of fluorescence assay methods in the late 1980s [13] and solid glass 
surfaces in the early 1990s [14,15] were significant improvements that laid the ground 
for modern microarrays and enabled faster and more precise analysis of signals. 
However, the major break-through that changed the whole field of genetic research 
came when photolithography [16] and printing [17], methods already used in the 
semiconductor industry, together with miniaturization and automation of processes, 
were applied to the manufacturing of microarrays. Miniaturization of the spots allowed 
better sensitivity and more genes to be analyzed from smaller amounts of samples [18]. 
The miniaturization of the array design also brought a massive parallelism, allowing the 
analysis of vast amount of genes in a single assay, which was a revolutional innovation 
and enabled the analysis of the whole transcriptome (i.e. all the expressed sequences in 
the human genome) in a single experiment. 
 
The history of modern solid-surface microarrays can be tracked down to 1995, when 
the first DNA microarrays with 45 cDNA probes were introduced by Schena et al.[17] 
The technological progress of the cDNA microarrays was extremely rapid; in 1996 
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publications with 1000 probes arrayed were already presented.[19-21] While 
impressive at the time, the pioneering company in the field has been Affymetrix (Santa 
Clara, CA, USA), which developed a novel technology of in situ hybridized 
oligonucleotide arrays based on photolithography combined with DNA-synthetic 
chemistry. [16,22,23] The use of light-directed synthesis to bind modified nucleotides 
to the chip surface enabled the manufacture of high-density oligonucleotide 
microarrays, which in 1996 contained already 135000 probes. Currently the 
GeneChip® (Affymetrix) expression microarrays are capable of containing millions of 
probes on a 1.28 cm2 surface of quartz, and mass production of whole genome chips is 
available for 16 organisms, including human, mouse, rat, dog, yeast, E. coli, C. elegans 
and A. thaliana, among others. The rapid development of various chip platforms is 
connected to the general development in bioinformatics, as automated sequencing 
methods and public databanks have made the annotated total genome sequences 
available for microarray probe designing and selection. 
1.3.3 Microarray fabrication 
The two most commonly used microarray systems have been the cDNA and 
oligonucleotide arrays, which differ in the used probe materials. The cDNA array 
probes are usually products of the polymerase chain reaction (PCR), generated from 
cDNA libraries or clone collections. The probes are printed on glass slides or nylon 
membranes as spots at defined locations, typically 100-300 µm in size and roughly 
equal distance apart from each other. However, due to the rapid completing of the 
human genome (HUGO) project, sequence information alone has become sufficient to 
generate the DNA to be arrayed and subsequently oligonucleotide arrays have replaced 
the cDNA arrays to a great extent. While the short oligonucleotide probes are prone to 
less specific hybridization and reduced sensitivity, they offer the design of probes that 
represent the most unique part of a given transcript, thus making the detection of 
closely related genes or splice variants possible. Affymetrix oligonucleotide 
microarrays, sometimes others as well, are referred to as high-density microarrays, 
reflecting the massive amount of probes they can contain in comparison to traditional 
cDNA arrays. The following chapters focus on the widely-used oligonucleotide arrays 
that can be manufactured by various methods, of which the most important are the in 
situ synthesis method for high-density oligonucleotide arrays (Figure 1) used by 
Affymetrix and Agilent Technologies (Palo Alto, CA, USA) and the contact and non-
contact (ink-jet) printing methods of presynthesized oligonucleotide probes used by 
many academic groups and commercial vendors.  
 
The multiple microarray systems available have been reported to show divergence in 
measured gene expression levels across the different platforms.[24,25] While varying 
degrees of correlation have been measured, the commercial platforms that have been 
compared appear to be moderately standardized and have showed reasonable 
correlations, at least when noise reducing strategies, such as filtering of low-level 
expressing genes, have been used.[24,26] The gene expression data correlation between 
custom-made and commercial platforms has been reported to be slightly lower, 
though.[24] 
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1.3.3.1 In situ synthesized high-density oligonucleotide arrays  
A photolithographic procedure to fabricate microarrays is used by Affymetrix for the 
GeneChip® microarrays, where a series of masks are used to synthesize 25-mer 
oligonucleotide probes onto a silicon wafer in such a manner that a large number of 
different sequences can be produced in parallel in a small number of 
steps.[16,22,23,27] The chip surface is first covalently modified with a silane reagent to 
provide hydroxyalkyl groups, which serve as the initial synthesis sites. The surface is 
then coated with a linker, which is a light-sensitive chemical compound that prevents 
coupling between the wafer and the first nucleotide of the DNA probe being created. In 
the next step, lithographic masks are used to direct light onto specific locations at the 
wafer surface to remove the protecting group from the exposed locations. The surface 
is subsequently flooded with a solution containing a modified base (A, T, C, or G) and 
coupling occurs only in those regions on the glass that have been deprotected through 
the illumination. The monomers are also protected at their 5’ positions with a 
photolabile group, so the cycle can be repeated. In this way, by using repeated cycles of 
photodeprotection and nucleotide coupling, a desired length of any given 
oligonucleotide sequences can be built on the microarray. In practise, the probe lengths 
are limited to 25 bases, as the yield of full length probes drops rapidly as the sequence 
is extended. 
 
The probes used for microarray synthesis are examined for specificity, potential for 
cross hybridization and predicted binding properties. To match the properties of the 
sample amplification procedure, the probes are 3’ biased, but typically widely spaced 
along the sequence. The GeneChip® contains two types of probes; Perfect Match (PM) 
and Mismatch (MM) probes. The PM is exactly complementary to the sequence of 
interest. The MM is identical to the PM except at the central 13th base position, which 
differs from the PM probe. In theory, the MM probe can be used to quantify and 
remove non-specific hybridization. The GeneChip® typically uses 11 to 20 probes to 
interrogate a given gene. This collection of probes is called a probeset, and is used in 
downstream analyses by Affymetrix to give a representative value for a gene 
expression. The in situ synthesis is a very powerful method; the process can achieve 
extremely high spot densities (spot size of 5 µm in 2005) and the probe sequence can 
be chosen more or less randomly for each synthesis. 
 
A competing method for the photolithography is the in situ synthesis of DNA 
microarrays by industrial inkjet printing process from digital sequence files. This 
technique has been adopted by Agilent Technologies (Palo Alto, CA, USA), and has 
the advantage of much longer probe sequences (60-100 bp) compared to the 
GeneChip®. The Agilent SurePrint Technology [28] is based on solid-phase 
phosphoramidite chemistry,[29] where the reactive sites on the nucleotides are blocked 
with chemical groups (dimethoxytrityl) that can be removed selectively. After the first 
base is printed, the trityl group that protects the 5’ hydroxyl group on the nucleotide is 
removed and oxidized to activate it, enabling it to react with the 3’ group on the next 
nucleotide. In between each step, the excess reagents are washed away to prevent 
random reactions later in the synthesis. The process of printing a nucleotide followed 
by de-tritylation, oxidation and washing is repeated 60 times. While the longer probe 
sequences guarantee better accuracy and precision for target hybridization, the spot 
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densities, however, are much lower (100-150 µm in size, at 100-200 µm center) than in 
light directed synthesis, mainly because of the natural limitation of liquid handling. 
 
A
T
G
T
T
A
T
C
C
G
G
T
G
C
A
A
T
G
T
A
T
C
G
G
T
C
A
A
C GA T
C GA T
T
G
T
C
G
G
T
C
A
A
C
A
T
C
C C
T
G
T
A
T
C
G
G
T
C
A
A
C C
T
G
T
A
T
C
G
G
T
C
A
A
UV-lightA
T
G
T
A
T
C
G
G
T
C
A
A
OxidationB
mask
ink-jet spotter
modified nucleotides
 
 
Figure 1. Schematic view of the typical “in situ” methods for microarray 
manufacturing. In the method used by Affymetrix (A) the probes are synthesized in 
repeated cycles using modified nucleotides and ultraviolet light. Photolithographic 
masks are used to selectively de-protect probes at given locations. In the method used 
by Agilent Technologies (B) the probes are synthesized using oxidative chemistry and 
ink-jet printing, where the nucleotides are fired from chambers containing a given 
nucleotide. 
1.3.3.2 Spotted microarrays 
The alternative for in situ synthesis is the use of presynthesized oligonucleotides that 
can be printed onto coated glass sides either with contact pins or by non-contact 
method using ink-jet technology, as mentioned earlier (Figure 2). These spotted 
microarrays can be custom made but are nowadays in increasing amounts commercially 
manufactured by a number of vendors. Microarray fabrication using contact printing is 
based on computer controlled robotic arms linked with a head of high definition pins or 
capillary devices.[17] The pins pick up small drops of the probe solution from 
multiwell plates and carry them to the microarray surface. Upon contact with the 
substrate the small amounts of probe solution are released and deposited to the surface. 
In non-contact printing, small dispensing devices mounted on robotic arms use ink-jet, 
bubble-jet or piezo-electric propulsion [29-33] to transfer the oligonucleotides to the 
microarray surface. The ink-jetting technique does not require direct surface contact, 
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but operates on a “drop-on-demand” basis, firing small droplets of probe solution from 
miniature nozzles to precise locations on the substrate surface. 
 
Many factors, such as immobilization chemistry, spotting buffer, probe concentration 
and physical factors like spotter type, environmental conditions and the utilized pins 
influence the fabrication of DNA microarrays and have to be accounted for in the array 
design. Thus, whether using in situ synthesized or spotted arrays, the choice between 
platforms is an important decision, as this will affect the downstream operations of 
microarray sample processing and data analysis.  
 
contact printing
non-contact printing
A
B
 
 
Figure 2. Schematic view of the fabrication of spotted microarrays, where 
presynthesized oligonucleotides are used. In contact printing (A), high-definition pins 
deposit small volumes of probe solution directly on the array surface. In non-contact 
printing (B), the probe is delivered by propelling a small droplet of the solution from a 
miniature nozzle into the array surface. By repeating the cycles, large amounts of 
oligonucleotides can be printed with high definition. 
1.3.4 Microarray sample preparation and hybridization 
In microarray analysis, the mRNA expression levels in a sample are typically detected 
using a fluorescence detection system. This method relies on prepared RNA that has 
been tagged with a fluorescence label and can be detected with a scanning device. An 
important difference lies in the target preparation between the in situ synthesized 
oligonucleotide arrays (Affymetrix) and the spotted microarrays. In both cases, total 
RNA (or mRNA) is isolated from the source tissue or cells and converted to cDNA, 
labeled with a fluorescent dye, hybridized to the probes on the microarray and detected 
by phospho-imaging or fluorescent scanning. However, the high reproducibility of 
Affymetrix system allows accurate comparison of signals generated by samples 
hybridized to separate arrays using only one fluorescent dye (one-color array), while in 
the case of spotted arrays two different fluorescent dyes (such as Cy3 and Cy5) are 
used (two-color array). This procedure is schematically presented in Figure 3. 
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Figure 3. Overview of target preparation for spotted two-color arrays (cDNA and 
presynthesized oligonucleotide microarrays) and in-situ hybridized one-color arrays 
(Affymetrix). 
 
In the case of spotted microarrays, mRNA from two different cell populations or tissues 
(such as normal and tumor tissue) is converted to cDNA, which is labeled with 
different dyes in both samples. The labeled samples are then mixed and hybridized to 
the same array, which results in competitive binding of the target to the arrayed 
sequences. After hybridization, the slide is scanned using two different wavelengths, 
corresponding to the dyes used. Typically microarray scanners are scanning confocal 
microscopes, where the wavelength emitted by the fluorescent dye is captured in a 
photomultiplier tube. Hence, for cDNA microarrays, two fluorescence images of the 
chip are captured, which are merged to produce a composite image of the microarray. 
The image contains the measurements of the transcript levels ratios for each gene 
represented on the array. 
 
In the one-color target preparation process used by Affymetrix,[34] a reverse 
transcription procedure is used to produce double-stranded cDNA, which is in vitro 
transcribed and amplified to biotin-labeled cRNA. The biotinylated cRNA is then 
fragmented and hybridized on the chip. Following the hybridization, non-hybridized 
cRNA is removed from the array, and the chip is subjected to a series of washing and 
staining steps, where the fluorescent streptavidin-phycoerythrin (SAPE) dye binds with 
the biotin labeling of the cRNA. Finally, the array is scanned using a laser light, which 
excites the fluorescent staining agent. The result of a GeneChip® microarray scanning 
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is an image file that contains the recorded intensity values of each spot on the entire 
array, representing the emitted signal intensities that are relative to the amount of 
hybridized cRNA on the chip. 
1.4 Microarray data analysis 
1.4.1 Introduction 
The data analysis of a microarray experiment is a multi-step process and always 
dependent on the chosen experimental design. The complex process of sample 
preparation and hybridization in microarray analysis produces image files containing 
probe signal intensities, which require image analysis, signal adjustment and data 
normalization to correct for the non-biological variability (or noise) inherent in the 
system. These procedures are often joined together and referred to as “data 
normalization”. Due to the multiple microarray platforms with different target 
preparation and hybridization methods, numerous alternatives to implement these 
corrections have been developed. After preprocessing, the normalized gene expression 
data can be analyzed using statistical tools and exploratory methods to extract genes or 
patterns with  biological significance. The analysis of one-color and two color 
microarray data is more or less similar, the main difference between these methods lies 
in the normalization of the data. 
1.4.2 Image analysis and signal adjustment 
The image analysis of microarrays consists of a semi-automated procedure, where a 
computer-aligned grid is placed over the hybridized surface area. An image analysis 
software is then used to calculate the intensity of each spot or probe on the array and to 
store these measurements as numeric values into a text file. In the image analysis, the 
chip surface is also inspected for spatial hybridization biases and poorly hybridized 
spots to evaluate the hybridization quality and to eliminate these “bad spots” from 
further analyses. 
 
The term signal adjustment, also referred to as background correction, describes a wide 
variety of methods. This step is performed for mainly three reasons. First, to correct for 
the background noise and processing effect induced during the array hybridization. 
Secondly, to adjust for cross hybridization caused by the binding of non-specific target 
(DNA or RNA) to the array. Thirdly, to adjust for expression estimates so that they fall 
on the proper scale, or are linearly related to concentration. On spotted arrays the pixels 
surrounding the spot can be used to compute the background adjustment, whereas for 
Affymetrix GeneChips® the probe intensities are very densely spaced on the array and 
the probes themselves must be used to determine any adjustment required. For this 
purpose, Affymetrix uses a statistical algorithm called the Ideal Mismatch procedure, 
where the adjusted signal is calculated using the PM and MM probe intensities.[35] 
-24- 
1.4.3 Data normalization 
When dealing with experiments involving multiple arrays, inter-chip variation due to 
non-biological factors such as dye effects, sample or scanner differences, unequal 
quantities of starting RNA, etc. always exists. Normalization is a method that attempts 
to remove some of this variation. The idea behind normalization methods is that when 
comparing two or more samples on a genome-wide level, a vast majority of the gene 
expressions should remain unchanged and the data follow normal distribution. Thus, 
the expected mean intensity ratio between two channels (two-color data) or chips (one-
color data) should be one. If deviation is observed, the data is mathematically processed 
to adjust this ratio to one. Numerous algorithms and applications have been developed 
for data normalization, but a standard method for microarray data normalization has not 
been defined. Typical steps in microarray data normalization include a data 
transformation procedure to stabilize the variance of the intensity values across the 
dataset and to make the distribution more symmetric, a procedure to remove non-
biological variation within a single array, and a procedure to correct for non-biological 
variation between different arrays in a dataset. In addition, genes that are believed to be 
constantly expressed across a variety of conditions, often called house-keeping genes, 
or external control sequences from another organism, referred to as spike-in controls, 
can be used for normalization purposes. Biological and technical sample replicates are 
also utilized, and have been found useful in diminishing the effect of outlier samples 
and in enhancing the confidence of the data.[36] Robustness to the data is also achieved 
by utilizing summarized probe intensity values of multiple probes (one-color arrays) or 
replicate spots (two-color arrays) for expression measurements. Normalization is 
usually performed on the whole dataset, but can be based on either behavior of the 
whole data or only a subset of it. The selected method should depend on the prior 
knowledge or assumptions that are known regarding the behaviour of a particular 
dataset. 
 
For two-color microarrays, a constant adjustment, such as scaling or log centering, is 
often used to force the distribution of the intensity log ratios to have a median of zero 
for each slide. However, such global normalization approaches are not adequate in 
situations where dye biases can depend on spot overall intensity or spatial location 
within the array. In these situations dye-swap or locally weighted linear regression 
(LOWESS) smoothing are examples of typically used normalization methods. As each 
experiment has its own unique features and needs for normalization, many different 
methods for two-color arrays have been developed and are well documented in the 
literature.[37-42] 
 
For Affymetrix GeneChip® arrays, as mentioned earlier, probesets consisting of 
summarized probe intensity values are used to define a measure of expression 
representing the amount of the corresponding mRNA species. Several approaches to 
normalize expression data created with the GeneChip® system have been proposed, 
such as the model-based expression index (MBEI) used in dCHIP software,[43,44] the 
Microarray Suite (MAS) 5.0 statistical algorithm from Affymetrix [35] and the robust 
multi chip average (RMA) method by Irizarry et al. (2003).[45,46] These methods 
differ from each other considerably, and may lead to different results in data analysis. 
The MAS 5.0 algorithm uses a linear regression approach, where adjusted PM values 
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are log transformed and a robust mean is calculated on the resulting values. After 
obtaining a signal for each probeset as the antilog of the resulting value, the data is 
scaled using a trimmed mean.[47] In the method used by dCHIP, a chip with median 
intensity is selected as a baseline array for normalization. The algorithm uses an 
invariant set method, where a large number of probes are selected ad-hoc as references 
for comparison of two samples and a non-parametric curve (running median) is fitted 
through the datapoints. The most recently introduced normalization methods are the 
RMA and GCRMA, a modification of this method,[48] which use quantile 
normalization to give the same empirical distribution of intensities for each array in the 
experiment. In the quantile normalization medhod, the highest background corrected 
and log-transformed PM intensity on each GeneChip® is determined. These values are 
averaged, and the individual values replaced by the average. This process is then 
repeated for all intensities in descending order. Following the quantile normalization, 
an additive linear model is fit to the normalized data to obtain expression measuse for 
each probe on each GeneChip®. The modified GCRMA method takes also advantage 
of sequence information to appropriately describe nonspecific background variation. 
 
Due to the wide range of methods and applications available for data production and 
normalization, quality and comparability of the analysis results of microarray 
experiments has become a major challenge. For this purpose, guidelines for microarray 
data reporting and standards for minimum information about microarray experiments 
(MIAME) [49] have been developed by the Microarray Gene Expression Data Society 
(MGED). The MIAME standards and deposition of the original datasets to a public 
database are nowadays by many journals considered as a prerequisite for publication of 
microarray data. 
1.4.4 Statistical analysis 
Microarrays can be used to investigate problems in cell biology in various ways, with a 
range of differential approaches. At the other end, the main interest lies in finding a 
single change in gene expression that might be a key to a given alteration in phenotype. 
At the other extreme, the aim is to look at overall patterns of gene expression in order 
to understand the architecture of genetic regulatory networks. The basic idea behind the 
statistical analysis is to characterize the structure of the experimental data and extract 
statistically significant patterns from it. Because of the complexity of the problems and 
datasets generated by microarray experiments, the use of data analysis software is 
essential. To date, a large number of commercial and non-commercial software tools 
for statistical analysis and visualization of gene expression data have been developed, 
which all offer their own solutions to the problem at hand. GeneSpring (Agilent 
Technologies), Cluster and Treeview,[50] GeneCluster,[51,52] SAM [53] and dCHIP 
[43] are examples of these software tools, to name a few. 
 
Methods utilized in the data analysis vary considerably. The analysis of microarray data 
is explorative by nature, and the components of the analysis depend upon the purpose 
of the experiment. Tools that are generally used include filters to remove redundant 
genes from the experiment, statistical tests to find differentially expressed genes and 
classification methods to discover pathway level expression patterns and find 
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distinguished expression profile signatures. The composition of a typical microarray 
data analysis is presented in Figure 4.  
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Figure 4. Overview of microarray data analysis for one-color and two-color 
microarrays. Due to the multiple different microarray platforms and experimental 
designs no standard protocol exists, and the composition of individual steps vary in 
each experiment.  
 
The expression of a large number of genes that are irrelevant or unchanged add a high 
level of noise and uncertainty to the data, which makes the use of classical statistical 
tests problematic. Reducing the number of genes in the analyses benefits the power of 
statistical testing. Gene filtering and differentiation approaches can efficiently reduce 
the dimensionality of the data and help remove redundant genes. This helps to highlight 
the genes that are truly differential for the investigated trait. Typical tests used in 
microarray analysis are parametric tests such as Student’s t-test or analysis of variance 
(ANOVA), which assume normal distribution of the data and try to estimate whether 
the variance in the data comes from the normal distribution or not. In addition, 
microarray experiments typically have large number of observations but only few 
samples that leads to testing of multiple hypotheses. As some of the observed 
differences are expected to happen by chance alone, correction for multiple testing is 
desired. These adjustements to the statistical tests include corrections such as the 
Bonferroni method and the false discovery rate (FDR) suggested by Benjamini and 
Hochberg (1995).[54] Permutation-based models are another approach to validate the 
results. Other methods for analysis include data transformations such as principal 
component analysis (PCA) and singular value decomposition (SVD), which reduce the 
dimensionality of the data and aim to find the major components explaining the 
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variance in the data. Fold change was among the first methods used to evaluate whether 
genes were differentially expressed, but is nowadays considered an inadequate test 
statistic when used alone, as it does not account for the variance and offers no 
associated level of confidence. The choise of an appropriate correction can be 
challenging, as many of the popular correction methods, such as the Bonferroni 
method, have not been designed for microarray data, where there are few cases but 
many obervations per sample. This may lead to very stringent correction and loss of 
data, with no false positive findings, but also very few true positive findings. Therefore, 
permutations and FDR based methods with adjustable threshold levels have gained 
popularity in validation of microarray analyses. 
 
Classification is a widely used analysis method for gene expression data, used either to 
discover new categories within a dataset or to assign cases to a given category, and is 
often referred to as clustering. Two principal categories of clustering exist: the 
unsupervised and supervised methods. In the unsupervised clustering (or class 
discovery), objects such as genes or samples are grouped into classes based on some 
sort of similarity metric that is computed for one or more variables. Typically, genes 
are grouped into classes on the basis of the similarity in their expression profiles across 
cases, tissues or conditions. Unsupervised clustering can further be split to hierarchical 
clustering methods, which produce a tree diagram (dendrogram) and non-hierarchical 
clustering methods such as self-organizing maps (SOM) or K-means clustering,[55,56] 
which typically divide the cases into a predetermined number of groups in a manner 
that maximizes a specific function. In the supervised clustering (or class prediction) 
methods, algorithms are developed to assign objects to predetermined categories. The 
supervised methods generally involve the use of a training data set and an independent 
validation data set, and aim to obtain a function or rule that uses expression data to 
predict whether a case is of one type or another. In cases where the dataset is too small 
to be effectively split, a cross-validation method such as leave-one-out or class 
permutation procedure is often used. 
1.4.5 Sensitivity and reliability in microarray measurements 
While the existence and direction of gene expression changes can be reliably detected 
for majority of genes in appropriate sensitivity ranges, accurate measurements of 
absolute expression levels and the reliable detection of low-level abundance genes are 
presently beyond the reach of microarray technology. [26] The detection limit of 
current microarray technology is estimated to be between one and ten copies of mRNA 
per cell, depending on the used microarray platform and target material. [57-59]  
 
Sources of inaccuracy and inconsistencies in microarray measurements and analysis 
include the probe sequence design, redundant annotation, splice variant effects, folding 
of the target transcript and cross-hybridization.[26,60] Recently it has been pointed out, 
that Affymetrix GeneChip® –based expression analyses suffer from probe and probeset 
annotation problems due to utilization of genomic information, which since the design 
of the chips has gone through a tremendous progress.[60] Due to the high variability in 
analysis methods and increased probability of false positive findings in microarray data 
analysis, data validation is generally regarded as an integral part of the analysis process. 
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Data validation can be either internal or external. In internal validation, the existing 
data is typically re-sampled, and probabilities are calculated on permutated sets of the 
data to evaluate the original findings. In external validation, the results are typically 
validated using another method on a new sample (or data) set, such as mRNA 
measurement of a number of selected genes by quantitative reverse-transcriptase PCR 
(RT-PCR), which is believed to protect against erroneous inferences due to 
measurement quality problems. Recently, though, this type of validation procedure has 
been questioned,[36] and it remains to be seen what the requirements for acceptable 
microarray results evolve to in the future. 
1.5 Cancer 
1.5.1 Introduction 
Tumor is a mass of abnormally proliferating (neoplastic) cells, which have no known 
purpose in the physiological function of the body. Two general types of tumors exist: 
benign and malignant. A benign tumor is composed of cells that may continue to grow 
in number abnormally but, unlike a malignant tumor, will not invade other unrelated 
tissues or organs of the body. A disease caused by a malignant tumor is referred to as 
cancer. 
 
Cancer is a disease of genes, where both external and internal factors, such as 
chemicals, radiation, viruses, hormones, immune conditions, lifestyle and inherited 
mutations, play a role in the formation of tumorigenetic mutations. The causal factors 
may act together, or in sequence, to initiate or promote carcinogenesis. It is estimated 
that worldwide there are 24.6 million people alive who have received a diagnosis of 
cancer in the last five years. Around half of these people live in Europe and North 
America. Each year over ten million people worldwide are diagnosed with cancer.[61] 
Cancer is a serious health problem, with annually increasing incidences. In Finland, 
prostate cancer is the most common cancer by incidence (5252 cases), with breast 
(3909), colorectal (2486), and lung (2157) cancers close behind (Finnish Cancer 
Registry, 2004). While the causes of cancer are gradually being understood, the 
mechanisms of carcinogenesis are still largely a mystery. 
 
Cancer is a group of diseases characterized by uncontrolled growth and spread of 
abnormal cells. Cancer can arise in different parts of the body. Cancers associated with 
the digestive system include cancers of the colon and rectum (colorectal cancer, CRC) 
and cancers of the pancreas, stomach and esophagus. Haematological malignancies 
(cancers of the blood, plasma and marrow) include leukemia and myelomas and 
cancers of the urinary system are bladder and kidney cancers. Lymphomas are cancers 
of the lymphoid system. Thyroid cancer is the most common type of tumour in the 
endocrine system (hormones), while brain and spinal tumours are found in the central 
nervous system. Sarcomas are related to the musculoskeletal system and named after 
the tissue of origin (bone, soft tissue, or connective tissue tumours). Skin cancers 
include melanoma and basal cell carcinoma, and head and neck cancers include those 
of the oral and nasal cavities. Some cancers are particular to men and women. Breast, 
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cervical and ovarian cancers are gynecological cancers found in women, whereas in 
men the reproductive neoplasms include prostate, testis and penile cancers.  
 
While the vast majority of the genetic alterations leading to cancer are somatic and 
found only in the tumors of the affected individuals, gene defects in the germline 
predisposing to cancer exist as well. Germline mutations are inherited from the parents 
and are present in every cell of the body. In the first case, where no predisposing 
inherited genetic factor is identifiable, the cancer is called sporadic. In the latter case, 
where an inherited mutation predisposing to cancer exists, the phrase hereditary cancer 
is used. Individuals with such mutations are at a higher risk at developing cancer, and 
are likely to do so at a younger age than in the general population, with an increased 
risk for multiple primary tumors.[62] In some cancers, as in CRC, patients with a 
familial risk can reach 20% of all cases.[63] 
1.5.2 Cancer and genes 
A cancer cell is a cell that has acquired mutations in critical genes, which allows a cell 
to escape the normal growth signals and proliferate in an uncontrollable manner. 
Cancer cells have defects in normal cellular functions that allow them to become 
malignant. Malignant tumors can be characterized by self-sufficiency to growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, tissue invasion and 
metastasis. In addition, the cells gain capabilities to invasion of other surrounding 
tissues and metastasis through the vascular or lymphatic systems.[64] Thus cancer cells 
may spread to new areas and organs of the body. 
 
Mutations in several genes are required for a cell to become cancerous. Mutation 
patterns at the cellular level can be either dominant or recessive. In the dominant case, 
an abnormality exists in only one of the two alleles of a gene and is sufficient to 
contribute to oncogenesis. Genes with this type of mutations are referred to as 
oncogenes, which are altered forms of normal cellular components called proto-
oncogenes. These genes control cell proliferation rates by their expression. Oncogenes 
acquire their tumorigenetic properties normally through "gain of function" –mutations 
such as activating point mutation, amplification or chromosomal translocation.[65] 
 
In a recessive mutation pattern, both alleles of a gene are inactivated. In this case, the 
genes are called tumor suppressor genes. Tumor suppressor genes can be divided into 
gatekeepers, caretakers and landscapers according to their function.[66,67] Gatekeepers 
are thought to directly regulate tumor growth by inhibiting proliferation or promoting 
cell death, whereas caretakers inhibit tumor growth indirectly by maintaining genomic 
integrity through DNA repair and replication. While the gatekeepers and caretakers are 
suggested to act at the intracellular level, the landscaper genes are speculated to be 
involved in tumorigenesis via intercellular signalling by generating an abnormal 
environment in the adjacent stromal cells. According to the two-hit hypothesis 
suggested by Knudson (1971) [68] both copies of the tumor suppressor gene have to be 
inactivated in order for the cell to turn malignant. The inactivation can be caused by 
mutations, chromosomal alterations, such as large deletions causing loss of 
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heterozygosity (LOH) of the gene locus, or epigenetic modifications. Epigenetic 
modifications are alterations in the genome that do not involve the DNA sequence 
itself.[69] Examples of epigenetic modifications include hypermethylation and loss of 
imprinting (LOI). Hypermethylation refers to the aberrant methylation of CpG 
dinucleotide bases of the promoter regions of the genes and has been associated to the 
transcriptional silencing of tumor suppressor genes.[70] LOI refers to gene silencing, 
where genes that show preferential expression of either maternal or paternal allele 
through a specific methylation pattern of the other allele lose this normal genetic 
imprinting. 
 
In this dissertation, two types of cancer were studied: a hereditary form of kidney 
cancer called Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC), and two 
classes of CRC: a locally advanced sporadic CRC and serrated colorectal carcinoma. 
These will be briefly introduced in the following sections. 
1.5.3 Hereditary Leiomyomatosis and Renal Cell Cancer 
HLRCC is an inherited cancer syndrome with predisposition to leiomyomas of the 
uterus and skin (benign tumors), uterine leiomyosarcoma and distinct papillary type 2 
renal cell carcinoma. The tumor predisposition is caused by heterozygous mutations in 
the Krebs cycle fumarase gene (FH).[71-73] Since the discovery of loss of wild type 
(WT) allele in tumors, the FH gene has been proposed to act as a tumor suppressor 
gene. However, the cellular and molecular mechanisms leading to tumor development 
remain unclear. Interestingly, families from Finland have displayed a phenotype with 
high risk of early-onset renal cell carcinoma and uterine leiomyosarcoma,[74] while 
this has not been the case in other populations.[75-77] The data from all examined 
populations are compatible with the notion that some families are very prone to 
malignant tumors, whereas others are not. [71,75-78] The most simple explanation for 
this is genotype–phenotype association, where the severity of the functional defect 
might relate to the occurrence of malignant tumors. However, modifier gene effects 
have been thought of as an alternative explanation. 
1.5.4 Colorectal cancer 
CRC is currently the only form of cancer where a model for tumor formation and 
progression has been described.[79,80] CRC has long been the most prospective cancer 
type for tumorigenetic studies, as many discoveries behind hereditary forms of the 
cancer, such as APC in familial adenomatous polyposis (FAP),[81,82] MLH1, MSH2, 
PMS2 and MSH6 in hereditary nonpolyposis colorectal cancer (HNPCC) [83-88] and 
LKB1 in Peutz-Jeghers syndrome (PJS),[89,90] to name a few, have provided clues to 
the formation of sporadic CRCs as well. Other genes relevant to the tumorigenesis of 
CRC are TP53, K-RAS and SMAD4. The TP53 tumor suppressor gene is important in 
maintaining DNA integrity and is thought to play an important role in the progression 
of CRC. Up to half of the colorectal cancers show mutations of TP53.[91,92] K-RAS is 
a mitogen activated protein kinase that transduces signals from receptor tyrosine 
kinases. Activation of the K-RAS oncogene has been implicated in colorectal 
carcinogenesis, and it is mutated in 30–60% of the adenocarcinomas. [93,94] The 
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chromosome arm 18q is deleted in approximately 50% of colorectal adenomas and 
70% of carcinomas. Initial target in the region was deleted in colorectal cancer (DCC), 
but later studies have implicated SMAD4 to be perhaps more important reason for these 
deletions.[95,96] In addition, germline mutations in SMAD4 predispose to familial 
colon cancer syndrome juvenile polyposis.[97] The development of cancer is a 
multistep process which may take years or even decades. Two well characterized 
pathways leading to CRC are the suppressor pathway and the mutator pathway. In the 
suppressor pathway, the tumorigenesis is thought to follow an adenoma-carcinoma 
sequence, where mutations in the wingless-type (Wnt) signaling pathway initiate a 
neoplastic process, and tumor progression through mutations in other genes leads to the 
development of an adenoma and finally a carcinoma.[79,80] Colorectal tumors 
evolving through the suppressor pathway often show large chromosomal instability 
(CIN), such as losses and amplifications of whole chromosomes.  
 
In the mutator pathway, the progression of colorectal tumors from adenoma to 
carcinoma is somewhat different. In majority of the cases, the chromosomal material is 
near diploid, and underlying causes for tumorigenesis are defects in the mismatch 
repair genes (MMR), which are responsible for maintaining the integrity of DNA in our 
cells. The MMR deficiency usually leads to microsatellite instability (MSI), which is 
observed as frequent insertions and deletions within short repetitive sequences 
(microsatellites) in the genome, where they are most apparent. Mutations in the coding 
region of a gene may result to altered reading frame and lead to disrupted protein 
function, which in turn may confer a growth advantage to the cell. Such mutations are 
typically desirable and selected, and can be found in a significant percentage of 
colorectal tumors with an MSI phenotype. Approximately 15% of the tumors of the 
colon and the rectum display MSI. Tumors where MSI is not observed are called 
microsatellite stable (MSS).  
1.5.4.1 Dukes’ C colorectal cancer 
CRCs are clinically diagnosed using either Dukes’ staging (A, B, C, D) or TNM 
classification (I-IV). These classifications define the stage of the tumor in terms of 
progression through the intestinal wall, spread to lymph nodes and distant metastasis, 
and are the basis of treatment selection. A large proportion of CRC patients is 
diagnosed with a disease with a regional lymph node metastasis (Dukes’ C stage) and 
routinely receives 5-FU-based therapy in combination with surgical resection due to a 
high risk of recurrence. However, the chemotherapy only benefits 10-20% of the 
patients.[98,99] Thus far it has not been possible to accurately separate the patients at 
high risk of recurrence. The use of adjuvant treatment has also complicated the study of 
prognostic factors that predict recurrence after surgery, because chemotherapy confuses 
the interpretation of results obtained with recent tumor collections. 
1.5.4.2 Serrated colorectal cancer 
The serrated colorectal tumors are a heterogeneous group of lesions that combine the 
architectural features of hyperplastic polyps and the cytological features of 
conventional adenocarcinomas. Hyperplastic polyps are common lesions found in 
around 12% of individuals over the age of 50 years [100,101] that have traditionally 
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been considered non-neoplastic and without malignant potential. While at least some 
serrated tumors appear to evolve through the classical Wnt signaling pathway,[102] a 
recently introduced serrated neoplasia pathway has been proposed to act as a previously 
underrecognized route leading to CRC.[103-105] According to this concept, neoplastic 
progression originates in the hyperplastic colorectal polyp and drives the accumulation 
of genetic changes within the lesion, which at the tissue level is thought to result in the 
development of a serrated adenoma and/or the emergence of colorectal carcinoma.[104] 
A number of studies describing events such as inhibition of apoptosis by decreased 
expression of CD95 (Fas),[106] MSI, [107-109] CpG island methylator 
phenotype,[110,111] allelic imbalance of chromosomal regions 18q and 5q,[112] and 
BRAF mutations [113] have been proposed to explain the characteristic serration of the 
lesions, but these studies have examined only few molecular features at a time. The 
serrated tumors may differ from conventional CRCs,[104,109] but the biological 
background of these tumors is still largely unknown. 
1.6 DNA microarray technology and cancer 
The new bioinformatics tools and development of genome-wide microarray analyses 
both in human, mice and other model organisms have opened new windows in cancer 
research. The field of gene expression studies has greatly advanced the identification of 
novel tumor susceptibility genes, classification of tumors, prediction of outcome, 
treatment response, discovery of potential markers and targets for diagnosis of this 
malignant disease. Microarray technology and the statistical tools developed for it are 
an excellent option to study mRNA expression differences of normal and tumor tissues 
or various tumors and model organisms on a global scale. Class discovery methods 
such as hierarchical or K-means clustering or self organizing maps [55,56] provide a 
global overview of the cell transcript levels and can be very useful in identifying novel 
markers for cancer or to identify important genes or pathways for tumorigenesis. Class 
prediction methods, on the other hand, provide detailed information of specific genetic 
signatures in various tumor subtypes, which may previously have been very difficult to 
characterize by conventional methods. Additionally, expression array technology can 
provide a tool to diagnose clinical cases which may have been difficult to identify 
otherwise. 
 
DNA microarray technology has expanded rapidly and has been applied to study 
several different types of human cancer, such as breast,[114-118] prostate,[119-121] 
colorectal [122] and ovarian cancer [123] as well as hematological 
malignancies.[52,124-126] A PubMed database search with keywords “microarray 
AND cancer” returned almost 4900 publications by August 2006, indicating the 
expansive use of microarray technology. (http://www.ncbi.nlm.nih.gov/entrez/) 
 
Landmark studies in the field of class discovery and prediction are the studies by Golub 
et al. (1999),[52] where they showed that two types of leukemias, acute myeloid 
leukaemia (AML) and acute lymphoid leukaemia (ALL) could be distinguished from 
each other based on gene expression profiling and a later study (2001) where they 
demonstrated that pediatric ALL can be subclassified into different groups with very 
different gene expression profiles.[126] In 1999 and 2000, Alizadeh et al. [124,125] 
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identified a diffused large B-cell lymphoma using “LymphoChip”, a chip designed 
specifically to profile a hematologic disease. In 2000 Perou et al. [114] published an 
article about molecular portraits of breast tumors where they classified tumours from 
42 individuals into distinguished subtypes by their gene expression patterns. The 
following year (2001) Sorlie et al. published a study about breast carcinomas and 
correlated tumor characteristics to clinical outcome using gene expression 
profiling.[115] Yet another study of importance is the one by van’t Veer et al. 
(2002),[116] where they were able to classify lymph node negative breast tumors into 
those with poor or good prognosis using a signature of 70 genes, with power that 
outstripped the available clinical prognostic markers. The impact of classification can 
be clinically very significant, as in prostate cancer (PC) where the surgical removal and 
risk that the surgery poses to these often older men has to be assessed. With molecular 
signatures being able to determine the possible outcome of the cancer these decisions 
can be greatly facilitated.  
 
The use of microarray technology together with supporting methods such as linkage 
analysis increases the power of the study, as this enables the researchers to define 
specific genomic area and focus the analysis on a certain part of the expression data. 
Examples of this include the nonsense-mediated mRNA decay (NMD) microarray 
strategy and combinatorial use of SNP microarrays and linkage analysis together with 
expression microarrays.[127,128] In eukaryotes, mRNA containing nonsense mutations 
are selectively and rapidly degraded by the NMD pathway during translation.[129] By 
pharmacological blocking of the NMD pathway, mutated transcripts containing 
premature termination codons are stabilized and accumulate in the cells, and the mRNA 
levels before and after treatment can be monitored using expression microarrays. In a 
study by Huusko et al. (2004) [130] NMD microarrays were used in combination with 
comparative genomic hybridization (CGH) microarray data to identify truncating 
mutations in the receptor tyrosine kinase gene EPHB2 in prostate cancer cell lines. 
Supporting analyses revealed frameshift, splice site, missense and nonsense mutations 
in clinical prostate cancer samples. Later publications have revealed this gene to be a 
putative tumor suppressor gene and inactivated also in CRC.[131,132] In a recent study 
by Vierimaa et al. (2006) [128] expression array data derived from peripheral blood 
extracted RNA was combined to linkage and SNP array analyses to identify a low-
penetrance tumor susceptibility gene AIP predisposing to familial pituitary adenomas. 
This was a new approach, and demonstrated that peripheral blood can be effectively 
used to identify predisposition to hereditary cancer of various origin. This has also been 
observed by us in microarray data analyses of HNPCC patients with MLH1 mutation 
and HLRCC patients with FH mutation (unpublished results). In principle, the use of 
blood as a source of RNA for expression arrays is in many ways desirable, as it is 
easily available and fresh, compared to tissue samples which can lead to tedious 
processing and result to poor quality arrays. Recently, blood derived RNA was also 
used in our expression array study where a genetic defect predisposing to a Xeroderma 
pigmentosum (XP) skin carcinoma disorder was discovered in a patient using only one 
affected and two non-affected chips (unpublished results). The disease in question 
could not be diagnosed using conventional methods, and demonstrated the diagnostic 
capabilities of expression arrays in cancer research.  
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Collectively, these studies serve to demonstrate the tremendous potential microarray 
technology has in cancer classification and clinical care. Numerous publications have 
appeared where class discovery has been utilised to distinguish different subtypes of 
various cancers, patient prognosis or response to treatment. While the microarray 
technology is most useful in providing transcriptional level information and genetic 
profiles, this is also the limitation of the technology. In general, other complementary 
techniques such as functional studies and/or sequencing of genomic DNA are often 
necessary to understand the molecular events involved and to gain mechanistic insight 
into the development or progression of cancer. The complexity and variability in data 
analysis and interpretation of the results, as well as the availability of sufficient quality 
RNA also remain obstacles in a wider clinical use of the technology. The possibility of 
using blood derived RNA, reducing the costs of the technology, and standardizing the 
array preparation and data analysis may provide an opportunity for a wider use of this 
approach in clinical practice and offer an additional tool in the search for new cancer 
susceptibility genes. 
-35- 
2 Aims of the Study 
Expression microarray technology, together with the recent development in 
bioinformatics and other biomedical research methods, is emerging as a promising tool 
in studies of human cancer. The aim of this work was to use expression microarray 
technology together with supporting methods in cancer research in studies of HLRCC 
and CRC.  
 
HLRCC is a syndrome caused by mutations in the gene encoding for fumarase (FH). 
While most families with FH mutations segregate a benign phenotype of multiple 
leiomyomas, others display an early-onset renal cancer and leiomyosarcoma, which 
may be due to modifier gene effects. In the first study (I) the aim was to perform a 
genome-wide gene expression profiling assay together with functional analyses to 
evaluate the effect of the FH mutation in yeast, and thus use it as a model organism for 
studies of HLRCC. 
 
A large proportion of CRC patients is diagnosed with a Dukes’ C stage disease and is 
treated with chemotherapy, which only benefits a fraction of the patients. Thus far, an 
accurate method to distinguish patients at high risk of recurrence has not been 
available. The second study (II) aimed to use gene expression profiling to identify 
molecular signatures that characterize tumors from Dukes’ C patients with good and 
bad prognosis. 
 
Serrated colorectal tumors differ from conventional adenocarcinomas morphologically, 
but not necessarily biologically. The third study (III) aimed to find out whether these 
two tumor types could be distinguished from each other based on their gene expression 
profiles and to subsequently identify key genes responsible for these differences. One 
of the interesting genes observed was ephrin receptor B2 (EPHB2). The role of EPHB2 
in CRC predisposition and the mechanisms of inactivation in colorectal tumors was 
further analyzed in the last two studies (IV and V). 
-36- 
3 Materials and Methods 
The materials and methods used in this work are presented in detail in the original 
publications (I–V). Here only essential procedures are described. 
3.1 Yeast strains (I) 
Six yeast strains, consisting of fumarase WT (FUM1, FUM1U), mutant (fum1H153R, 
fum1K187R) and knockout (fum1∆, fum1vect) strains, were created to study the effects of 
fumarase mutations. All strains were derived from a WT fumarase-containing 
Saccharomyces cerevisiae strain (FUM1) congenic to W303-1A. Fumarase gene 
knockout strain (fum1∆) was constructed from the WT strain using a PCR-targeted 
gene disruption method utilizing the kanMX4 module.[133] This knockout strain was 
used as a template for the creation of the 4 FUM1 mutated yeast strains by site-directed 
mutagenesis. Integrative yeast expression vector (pRS406) containing different 
versions of the FUM1 gene were integrated to the yeast genome by transformation that 
was carried out essentially as described previously.[134] The integration and copy 
number of the integrated genes were verified by Southern blotting.  
3.2 Clinical samples, healthy controls and cell lines (II-V) 
Majority of CRC cases used (II-V) came from a well characterized, previously 
described, consecutively collected and population-based series of 1042 Finnish fresh-
frozen colorectal tumor samples.[135,136] In Publication II, 281 Dukes’ C  patients 
from this series were selected, of which 25 were used in the microarray analysis. In 
Publication III, 45 serrated and 115 conventional CRCs from the above mentioned 
series and from another well characterized and population-based Finnish collection of 
466 cases [109] were utilized. Of these, 37 were used on the microarrays.  
 
In Publication IV, 101 normal tissue samples from medical institutions in Finland, UK 
and USA from patients with 1) CRC and a personal or family history of PC, or 2) 
intestinal hyperplastic polyposis (HPP) were utilized in the initial mutation screening. 
The observed alterations were further examined in either Finnish familial prostate 
(n=164) and colorectal (n=159) cancer patients, or in additional UK HPP patients 
(n=40), respectively. The Finnish CRC patients belong to the aforementioned 
population based series of CRC patients.[135,136] The familial PC cohort has also 
been previously well characterized and described.[137,138] In addition, 282 samples 
from anonymous Finnish blood donors and 200 healthy UK individuals served as 
population-matched controls, respectively.  
 
In Publication V, 246 clinical samples collected at medical institutions in Finland, 
Spain, Germany and Japan were utilized. The MSI status of these tumors was 
characterized as previously described.[135,136,139,140] The cell lines used in this 
study were obtained and maintained as previously described.[141] 
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3.3 Microarray preparation and hybridization  
3.3.1 YG-S98 expression microarrays (I) 
RNA extraction was done from 30 ml YPD cultures harvested at A600 3.0 by 
homogenizing the samples with glass beads in a breaking buffer (20 mM Tris-HCl pH 
7.5, 0.1 M KCl, 2 mM MgCl2, 2 mM DTT). Total RNA was isolated from the lysate 
with RNEasy spin columns (Qiagen, Valencia, CA). The quality of RNA was analyzed 
using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Hybridizations 
to the GeneChip YG-S98 arrays were done according to the manufacturer’s instructions 
using 8 µg of total RNA as starting material (Affymetrix, Santa Clara, CA). 
Hybridization quality was controlled by inspecting that on each array the number of 
probes present on the chip, the 3’–5’ ratios of the hybridization controls (BIOB, BIOC, 
BIODN, CREX), average background intensity and noise were on similar levels. Probe 
sets with unsuccessful hybridization were left out of analyses by masking them out 
using the MAS 5.0 software (Affymetrix). 
3.3.2 HG-U133A expression microarrays (II , III) 
Frozen tissue samples were macrodissected from the selected areas of the frozen OCT 
blocks and homogenized in 1 ml of Trizol reagent (Invitrogen, Carlsbad, CA) with a 
tissue homogenizer (Ultra-Turrax T8; IKA Labortechnik, Staufen, Germany). The total 
RNA was further purified using RNeasy spin columns (Qiagen). The RNA quality was 
analyzed using Agilent 2100 Bioanalyzer (Agilent Technologies). Biotin labeled and 
fragmented cRNA was prepared from 8 µg of total RNA with procedures 
recommended for the HG-U133 GeneChip expression analysis (Affymetrix). The HG-
U133A chips were hybridized, scanned with GeneChip Scanner GA2500, and analyzed 
with MAS 5.0 software according to the manufacturer’s instructions (Affymetrix). The 
hybridization quality of the chips was inspected by looking at the chip control values, 
which met the thresholds set by the Tumor Analysis Best Practices Working 
Group.[142] 
3.4 Expression microarray data analysis 
3.4.1 Statistical analysis of the YG-S98 arrays (I) 
The expression data were normalized by centering array intensities on the median. 
Gene expression values were then scaled by dividing the expression measurement 
values on each chip with the corresponding control sample value (FUM1). The 
normalized expression data were filtered to remove expression values below detectable 
levels using the Affymetrix Detection Algorithm assigned flag calls. Subsequent 
analyses were restricted to genes with detectable expression in all 6 strains. The effect 
of biological variation resulting from strain processing and transformation methods 
such as heat shock treatment and insertion of bacterial DNA-containing vector was 
accounted for by filtering out genes with over 20% deviation in the expression values 
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between the created WT strain (FUM1U) and the original WT strain (FUM1), resulting 
to a list containing 2113 genes. The threshold for differentially expressed genes was set 
to genes from this list with at least 2-fold change in the expression value of mutant or 
deletion strain in comparison to the FUM1U strain. The data was processed with 
GeneSpring 7.0 software (Silicon Genetics, Redwood City, CA). 
3.4.2 Statistical analysis of the HG-U133A arrays (II , III) 
The expression data were normalized by centering first the array and then the gene 
intensities to their corresponding medians. The normalized data was filtered to remove 
expression values below detectable levels using the Affymetrix Detection Algorithm 
assigned flag calls. 
 
In Publication II, the data analyses were restricted to genes with detectable expression 
levels in at least 50% of the samples (10035 genes). In samples with absent calls the 
gene expression was substituted with the average gene expression across all samples to 
allow class permutation analysis as previously described.[53] Genes differentially 
expressed in patients with good and bad prognosis were identified with a Student’s t-
test. Results validation used random permutation of the class labels, where the 
frequency of events when a p-value was lower than the initial p-value was calculated in 
one million permutations. Genes that were found to have a p-value lower than the 
initial p-value in <1% of the permutations were selected as differentially expressed. 
 
In Publication III, the data analyses were restricted to genes with detectable expression 
in at least 29 of 37 samples (78%), which allowed inclusion of genes absent in the 
serrated samples while removing noise from the data. A total of 7928 genes fulfilled 
these criteria. Genes differentially expressed between the serrated and non-serrated 
CRC groups were identified by performing a Student’s t-test and a Benjamini and 
Hochberg multiple test correction.[54] The data was processed with GeneSpring 6.2 
software. 
3.4.3 Functional gene enrichment analyses (I, II, III) 
In functional group enrichment analysis (FGEA), Gene Ontology terms [143] were 
used to annotate genes based on their biological processes, cellular components, and 
molecular functions. Fisher’s exact test was then performed to find out whether any of 
these categories were enriched in a list of differentially expressed genes, when 
compared to a list of all the annotated genes in that experiment. The analyses were 
implemented in the GoMiner software.[144] 
 
In Publication I, the analysis was done in each of the mutant and deletion strains by 
comparing a list of 270 differentially expressed genes to a starting list of 2113 genes 
that were comparable in all the arrays. Genes that belonged to a category that had a 
Fisher’s exact test p-value less than 0.05 and were over 2 fold over- or underexpressed 
in comparison to the WT strain FUM1U were considered enriched. 
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In Publication II, all genes with present calls in at least 50% of samples (10035 genes) 
were used for the annotation. This list was compared to a list of 218 unique genes 
differentially expressed in tumors from patients with good and bad prognosis. 
Categories with <5 genes or >500 genes were removed from the analysis, as they were 
considered to be too specific or too general to be useful. Categories with a p-value less 
than 0.01 were considered enriched. 
 
In Publication III, genes with detectable expression in at least 29 of 37 samples (7928 
genes) were used for the annotation and the resulting list compared to a list of 226 
differentially expressed genes in serrated versus conventional CRCs. Categories with a 
p-value less than 0.01 were considered enriched. 
3.4.4 Unsupervised hierarchical clustering (II, III) 
In Publication II, 5102 genes that were expressed at detectable levels in all 25 samples 
were selected. The raw expression data for these genes was imported to the Cluster 
software, log2-transformed and the intensity of both the arrays and the genes were 
centered to the median. Subsequently the transformed data was hierarchically clustered 
there and visualized with TreeView software.[50] 
 
In Publication III, a total of 7928 genes detected in 78% of the samples were used in 
the unsupervised hierarchical clustering that used Spearman’s rank correlation as the 
similarity metric. Both the clustering and the visualization of the normalized data were 
implemented in GeneSpring 6.2. software. 
3.4.5 Class prediction analyses (II, III) 
The class prediction analyses were used to test whether a small set of genes could be 
used to distinguish the tumor subtype of an unknown sample based on the expression 
profiles of a training set of samples. The analyses were implemented by using the 
GeneCluster II software.[51,52] The predictors were generated using a K-nearest 
neighbors (KNN) classifier and validated with a leave-one-out cross-validation 
procedure as previously described.[52,141,145]  
 
In the prediction of Dukes’ C recurrence (II), the list of 5102 genes expressed at 
detectable levels in all 25 samples were used for these analyses. Each gene profile was 
discretized independently to binary values across the samples by applying the Lloyd 
algorithm.[146] The Lloyd algorithm minimizes the average discretization error, which 
represents the distance between the data and the discrete representation. This algorithm 
can be understood as a particular case for 1-dimensional data of the K-means clustering 
method. The number of genes used in this classifier varied from 1 to 100, and the 
number of neighbors varied from 1 to 10. The classifier was further validated by using 
a random permutation of the class labels, which gave an estimate of the average 
prediction accuracy of the classifier. 
 
In the molecular classification of serrated CRC (III), the predictor was built in using a 
list of 4413 genes detected in all 37 samples on the microarrays, 3 nearest neighbors 
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with signal-to noise feature selection (mean class estimate) and a 1/k weighting 
method, which weighs neighbors by the reciprocal of the rank of the neighbor's 
distance. 
3.5 Supporting methods 
3.5.1 Functional studies of the yeast strains (I) 
The yeast strains were routinely grown on YPD media at 30°C. For plate growth tests 
yeast cultures were grown on fermentable, partially fermentable and non-fermentable 
carbon sources. The fumarase enzyme activities were measured from cell lysates by 
calculating the amount of NAPD consumed in the fumarate-to-malate reaction as 
previously described.[147] The fumarase protein production was determined by 
western blotting. The yeast cell cultures were grown on YPD media and collected at 
A600 2.0. The methods are described in detail in the original publication (I).  
3.5.2 Immunohistochemistry and tissue microarray (II, III) 
For the immunohistochemical (IHC) assessment of RHOA expression levels in Dukes’ 
C colorectal tumors (Publication II), an independent set of formalin-fixed, paraffin-
embedded samples from 137 Dukes’ C colorectal tumors and 16 lymph node 
metastases was used. The experiment was done on a tissue microarray that contained 
triplicate sections of each tumor sample in a fresh paraffin block. The correlation of 
RHOA staining level to the survival data was calculated using the mean survival, the 
hazard ratio and the log-rank p-values in the data set. Details of these analyses are 
explained in the original publication (II). 
 
The IHC staining of ephrin receptor B2 (EPHB2), patched (PTCH), hypoxia-inducible 
factor 1-alpha (HIF1α), cyclin T2 (CCNT2), metastasis associated 1 (MTA1), and 
methyl-CpG binding domain protein 4 (MBD4) were done in a training set (TS) and a 
validation set (VS) of samples utilizing paraffin embedded tissue blocks (Publication 
III). The TS consisted of the 37 (8 serrated and 29 conventional) CRC samples that 
entered expression array analysis while the VS included a separate set of 37 serrated 
and 86 conventional CRCs from the same collections. These antibodies were chosen 
based on observed differential expression at the RNA level, relevance of their 
biological function, and the commercial availability of the antibodies. Detailed 
procedures are explained in the original publication (III). 
3.5.3 Quantitative RT-PCR (II) 
Real-time reverse transcription polymerase chain reactions (RT-PCR) were done from 
aliquots of RNA (100 ng) using SuperScript II enzyme according to the manufacturer’s 
recommendations (Invitrogen). An aliquot of undiluted RT-PCR product (5 µl) was 
used to PCR-amplify the RNA with Assays-on-Demand TaqMan primers and probes 
and TaqMan Universal PCR Master Mix in a GeneAmp 5700 Sequence Detection 
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System (all from Applied Biosystems, Branchburg, NJ). Relative gene-expression 
levels were quantified with the ∆∆CT method with β-actin as a housekeeping standard 
control, as previously described.[141,148,149]  
3.5.4 Mutation analyses and allelic imbalance (II, III, IV, V) 
In the Dukes’ C recurrence study (II), an extended set of 46 fresh-frozen CRC samples 
were screened for K-RAS and TP53 mutations and were assessed for allelic imbalance 
in chromosome 18q by direct sequencing. Two polymorphic microsatellite markers in 
18q21 (D18S1110 and D18S1156) were used to assess the allelic imbalance in this 
region, as previously reported.[149,150] Allelic imbalance was scored if there was a 
difference >40% in the abundance of an allele between normal and tumor 
samples.[150,151] The mutation hotspots of K-RAS (codons 12, 13, and 61) were PCR-
amplified as described previously.[152,153] Exons 2–11 of TP53 were PCR-amplified 
as previously described.[145,154] The complete coding sequences of RHOA (exons 2–
5) were sequenced in 5 of the tumor samples that showed the highest RHOA protein 
levels and in 5 of the tumors with the lowest expression.  
 
The mutation analysis of EPHB2 gene was done by direct screening of the genomic 
DNA as described in the respective publications (III, IV, V). Loss of heterozygosity 
(LOH) was scored in cases displaying single nucleotide polymorphisms (SNPs) by 
comparing sequences from the normal and the corresponding tumor DNA (III, IV). 
Frequencies of the observed alterations in familial CRC, PC and HPP patient samples, 
as well as in healthy population-matched controls, were determined by either direct 
sequencing or DHPLC (IV). 
3.5.5 Methylation analysis and western blotting (III, V) 
The DNA methylation status of the EPHB2 promoter-associated CpG islands was 
determined by chemical conversion of unmethylated cytosines to uracil with bisulfite as 
previously described.[155] EPHB2 promoter region was defined and primers created 
for it with Promoter Scan and MethPrimer software.[156,157] In vitro methylated DNA 
(CpG Genome Universal Methylated DNA; Chemicon International, Temecula, CA) 
was used as a positive control for methylated alleles, whereas DNA from normal 
lymphocytes and normal colon tissues were used as negative controls. The detailed 
procedures are presented in the relevant publications (III, V). 
 
The EPHB2 western blotting was done on SW620 cultures treated with varying 
amounts of the DNA methyltransferase inhibitor 5-aza-2´-deoxycytidine for 72 hours 
and probed with an anti-EPHB2 antibody (Stratagene, La Jolla, CA). The membranes 
were then stripped and reprobed with an anti-β-actin antibody (clone AC74; Sigma, St. 
Louis, MO), which was used as a loading control. The analysis is described in detail in 
the original publication (V). 
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4 Results and Discussion 
4.1 Modeling tumor predisposing FH mutations in yeast (I) 
In this study, genetically modified yeast strains were used to study the effect of two 
conserved fumarase mutations; H153R, which has been described in 3 cancer 
predisposition families and K187R, which has displayed the benign phenotype in 3 
reported families,[72,74] to assess whether cancer-related fumarase mutations differ 
from their benign phenotype-associated counterparts. 
4.1.1 Expression microarray profiling of the yeast transcriptome 
In total, the microarray analysis of the 6 strains identified 2113 genes with comparable 
expression data between the yeast strains. Of these, 270 probes representing 173 genes 
and 97 poorly characterized sequences were found to be differentially expressed in the 
mutant and knockout strains in the yeast transcriptome. The differentially expressed 
genes belonged to categories related to cell respiratory functions and cell cycle 
regulation. Genes responsive to fumarase mutations or deletion were composed of 
multiple categories with functions integral to cell regulation, respiration, GTPase 
activity and mitochondrial trafficking. In analysis of genes regulating the cell cycle, 
108 genes were found from the list of 2113 genes. Of these, 11 genes were found to 
have over 2 fold changes in at least 1 of the mutant strains (fum1H153R, fum1K187R or 
fum1vect) in comparison to the WT strain (FUM1U). However, on a pathway level, no 
significant differences could be distinguished. 
 
A functional gene enrichment analysis performed on strains fum1H153R, fum1K187R and 
fum1vect found 116 functional groups enriched in the 270 differentially expressed genes 
(p < 0.05). Although only one group was common to all strains, multiple genes inside 
the groups were overlapping with significantly enriched groups in the other strains. The 
analysis indicated that the mutant strain fum1K187R and the knockout fum1vect resembled 
each other more closely than the other mutant strain fum1H153R, which had fewer groups 
in common with the other strains. 
4.1.2 Effect of fumarase alterations to the Krebs cycle gene expression levels 
The 15 yeast Krebs cycle genes were in general expressed at a decreased level in the 
knockout (fum1vect) and mutant (fum1H153R and fum1K187R) strains with the mutant 
strains showing greater decrease. The only exception to this was the IDH1 gene, where 
levels from both of the mutant strains fum1H153R and fum1K187R as well as the knockout 
strain fum1vect showed increase in expression relative to the WT fumarase-containing 
strain FUM1U. The mutant strains also showed decrease in expression levels in all of 
the 4 SDH subunit encoding genes, KGD1 and KGD2 as well as LPD1. As expected, 
there was no detectable fumarase expression in the knockout strain fum1vect. After 
adjustment for copy number effects, no significant differences in fumarase expression 
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were seen in the mutant strains fum1H153R and fum1K187R in comparison to the WT strain 
FUM1U. 
4.1.3 Functional studies 
In the literature, both heterozygous and homozygous mutations in the human fumarase 
gene (FH) causing both modifying and truncating forms of protein with different levels 
of enzyme activities have been described.[71,158] Previously, the K187R mutation has 
been one of the few mutations examined in homozygous state in human cells and 
shown to cause decreased activity.[158] Consequently, the effect of these mutations on 
fumarase activity in yeast carried out in this study, was of great interest. 
 
The in vitro fumarase enzyme activities indicated that the fumarase activity levels 
differed considerably between the strains. The activity was highest in the WT strain 
FUM1U and had dropped to a 1/11 fraction in the mutant strains fum1H153R and 
fum1K187R. Both mutants had similar fumarase activity levels. The deletion strains 
fum1∆ and fum1vect showed no detectable activity. The western blotting results, 
however, showed fumarase protein in the WT strains FUM1 and FUM1U as well as in 
the mutant strains fum1H153R and fum1K187. In agreement with the lack of fumarase 
mRNA observed, in the deletion strains fum1∆ and fum1vect, no fumarase protein was 
observed. 
 
To examine whether the detected residual fumarase activity was physiologically 
meaningful, the created yeast strains were tested for growth phenotype using 
combinations of carbon sources that were made gradually less fermentative. On 
fermentative carbon sources all strains had similar appearances, but when grown on 
less fermentative media the colonies formed more slowly and different phenotypes in 
appearances were observed in the knockout and mutant strains. On a nonfermentative 
carbon source the fumarase knockout strains fum1∆ and fum1vect could not grow due to 
the loss of mitochondrial respiratory chain function, while the fumarase mutant and WT 
strains showed normal growth. 
 
Due to the observed differences in growth abilities on nonfermentative plates, the yeast 
growth rates were measured also from liquid cultures for the WT and deletion strains. 
While the results indicated a trend towards knockout strains dividing faster than the 
WT strains, no statistical significance could be demonstrated by t-test. 
4.1.4 Evidence of a modifier effect in HLRCC 
Fumarase defects have been found to predispose to an autosomal dominant tumor 
predisposition syndrome HLRCC,[71-73] but the exact molecular mechanisms linking 
defective FH to malignant tumors are not known. The question on relation between FH 
defects and cancer is further complicated by the uneven occurrence of renal cell 
carcinoma and uterine leiomyosarcoma in families segregating FH mutations.[74] This 
could be explained by phenotype-genotype correlations, e.g. only severe mutations 
predisposing to cancer. However, as the same mutation can occur both in cancer 
predisposed and apparently low-risk families, modifying genes could equally well 
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explain the cancer phenotype. We addressed this issue by comparing the effects of 2 
fumarase mutations, H153R with high-penetrance cancer predisposition and K187R 
with benign phenotype association, in a yeast background. 
 
Microarray studies of the yeast strains consisted of a global analysis of genes most 
differentially expressed in the mutant and the knockout strains. Functional gene 
enrichment analysis was further used to look for pathway level differences. The array 
results reflected observations seen in activity assays and growth tests. When expression 
levels of cell cycle regulating genes were analyzed in different fumarase mutants, no 
significant differences were observed on a pathway level between the mutant strains. 
This correlates well with the finding that no growth rate differences were observed 
between the mutants. The expression level of most Krebs cycle genes was decreased 
and in general comparable to previously published results of fumarase knockout 
yeast.[159] The expression level decrease was more severe in the mutants, which may 
result from the fumarase point mutations. It was of interest to note that while fumarase 
mRNA and protein expressions were on comparable levels in both the mutants and the 
WT strain, a considerable difference was seen in the enzyme activities. Thus, although 
being partially defective, fumarase could still display interactions with other cellular 
components possibly even unrelated to respiration, such as cytosolic forms of the Krebs 
cycle enzymes or other yet unknown interaction partners. Interestingly, the array results 
on Krebs cycle IDH1 gene expression levels were similar to those reported in human 
FH deficient myomas,[160] indicating that the mutations in the yeast fumarase may 
have similar effects to those observed in patients with HLRCC. This was true for the 
functional gene enrichment analysis results as well, where overlapping categories, such 
as oxidoreductase activity and carbohydrate metabolism were similarly affected in the 
yeast model system and in the human myomas with FH mutations.  
 
The key observation of the study was the residual activity of the missense mutated 
fumarase proteins, which was physiologically relevant and similar in both the renal 
cancer and uterine leiomyosarcoma phenotype-associated H153R mutant and in the 
K187R mutant associated with the benign form of HLRCC (multiple cutaneous and 
uterine leiomyomatosis). This finding supports the hypothesis that HLRCC is not a 
classical one gene cancer predisposition syndrome with genotype-phenotype variations 
in severity, but that modifier genes appear to play a role in genesis of malignant tumors 
in the context of FH germline mutations. 
 
On a more general level, this study demonstrated the applicability of a yeast model in 
an expression array study of the HLRCC syndrome. The S. cerevisiae as a model 
organism was found to be an adequate system; as an extensively studied eukaryote with 
a known genome,[161,162] yeast was a very approachable tool to study the molecular 
and cellular mechanisms of HLRCC. While the statistical analysis of expression data 
did not reveal candidate genes for the modifier hypothesis, it still supported the current 
view of Krebs cycle defects playing a major role in tumor predisposition. 
Retrospectively, the lack of biological replicates was a drawback in the array 
experiment, as it diminished the power of the statistical analysis. However, the 
resources available for these studies did not allow an experimental design with multiple 
replicates. By using more replicates per strain, more sophisticated analyses and better 
estimations of population mean expression levels could have been done, which would 
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have increased the confidence of the findings. Additionally, the study demonstrated that 
while the gene expression levels provided a global and accurate report of the 
transcriptional level events, the expression array technology was incapable to capture 
the translational level aspect of protein inactivity; fumarase mRNA and protein was 
expressed at comparable levels, but showed only minimal residual activity on enzyme 
assays. Thus, finding a gene which might be related to the HLRCC phenotype in 
humans by microarray studies can be challenging, as no prior assumptions of function 
or expected expressional differences are available. The usefulness of the expression 
arrays was linked to the utilization of other supporting methods, which together provide 
very useful expressional level information that can be used in further studies of 
HLRCC. In the future, by combining additional methods and information from other 
studies, the yeast array data could further benefit the search of a HLRCC modifier 
gene. A prospective study would be an experiment with yeast strains with both homo- 
and heterozygous mutations (in diploid yeast strains) or strains with the yeast fumarase 
replaced by the human fumarase gene. 
 
In the literature, microarray technology has been successfully used in kidney cancer 
studies to profile different kidney cancer types and normal tissue,[163] and distinguish 
prognosis for papillary type 1 and 2 tumors,[164] but few studies exist of HLRCC. In a 
study by Vanharanta et al. (2006),[160] sporadic and familial FH mutation harbouring 
leiomyomas were compared to tumors with no FH mutations by microarray profiling. 
In this study, gene expression profiling clustered the tumors with sporadic and familial 
FH mutations together in a same cluster, while the tumors without FH mutations 
clustered separately on their own branch, demonstrating that HLRCC tumors were 
different from other leiomyomas. Interestingly, one heterozygous sample where one 
allele had a mutation while the other was intact clustered together with the FH mutation 
negative samples, indicating that two hits could be required to the formation of a 
HLRCC expression profile. In another study by Yang et al. (2005) [164] papillary type 
1 and 2 renal cell cancers were distinguished from each other using supervised 
clustering. Based on the classifier used in that study, a renal cancer cell line with 
fumarase mutation used in our further studies was by the other group identified as a 
papillary type 2 tumor (B. Teh, personal communications), which is also the renal 
tumor type typically seen in HLRCC. However, relatively little is known of the 
mechanisms of HLRCC tumorigenesis, and thus far classification of the HLRCC 
syndrome relies on conventional genetic and functional studies to characterize the 
typical features of the syndrome.[74] 
4.2 Prediction of recurrence in Dukes’ C colorectal cancer (II) 
In this study, fresh-frozen tumor samples from Dukes’ C stage CRC patients with 
surgery as the only form of treatment were subjected to microarray analysis to identify 
patterns of gene expression that characterize tumors from patients with good and bad 
prognosis.  
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4.2.1 Differentially expressed genes and functional group enrichment analysis 
Altogether 10035 probes were selected for statistical analysis, of which 236 sequences 
were identified as differentially expressed between patients with good and poor 
prognosis. Of these, 160 had lower expression and 58 had higher expression in tumors 
from patients with poor prognosis compared with tumors from patients with good 
prognosis. Gene ontology (GO) terms were used to classify all these 10035 sequences 
into 1385 GO categories. Functional group enrichment analysis of the differentially 
expressed genes identified 24 partially overlapping subcategories with a p-value < 0.01 
among the 1385 gene categories tested. These overlapping subcategories could be 
grouped into 6 main functional groups: protein transport, protein folding, transfer RNA 
(tRNA) ligase activity, chemotaxis, muscle contraction, and negative regulation of 
enzyme activity. Most of the genes in protein transport category were involved in 
vesicle trafficking, a process that regulates multiple signaling mechanisms and has 
previously been linked to tumorigenesis.[165,166] The remaining genes in this 
category were involved in nuclear transport, mitochondrial transport, or endoplasmic 
reticulum trafficking, which are processes previously shown to be deregulated in 
CRC.[167-169] Protein folding category genes ensure that proteins are correctly folded 
to be functionally active and play an important role in tumorigenesis.[170-172] The 
tRNA aminoacylation synthetases are essential in protein synthesis but has recently 
been realized to have important additional functions in key processes such as tRNA 
processing, RNA splicing and trafficking, ribosomal RNA synthesis, apoptosis, 
angiogenesis, and inflammation.[173,174] 
4.2.2 Molecular signatures for good or bad prognosis 
The class discovery by unsupervised hierarchical clustering of the 25 samples divided 
the dataset into three sub-branches. Using 5102 genes, most of the patients with bad 
prognosis (7 of 10) clustered together in one of the main sub-branches while a great 
majority of the patients with good prognosis (12 of 15) clustered in the other 2 sub-
branches. Moreover, a significant difference (p-value = 0.019) was observed in the 
disease-free survival of patients with good and bad prognosis.  
 
In class prediction, a KNN–based classifier using a combination of 17 genes from a set 
of 72 genes was able to predict the prognosis of 22 of the 25 samples (88%) correctly in 
our data set. The classifier was built from genes on basis of differential expression 
levels between the two groups. The sensitivity and specificity of this classifier to 
identify patients with poor prognosis were 80% and 93.3%, respectively. Importantly, 
this classifier was able to identify 2 groups of patients with significantly different (p-
value = 0.0001) disease-free survival after surgery.  
 
The microarray-based expression profiling outperformed other genetic markers 
previously investigated, such as p53 and K-RAS status or allelic imbalance in 
chromosome 18q,[175-184] which in this study showed limited prognostic power in an 
extended sample set.  
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4.2.3 RHOA as a prognostic marker in Dukes’ C colorectal cancer 
In this study, statistical analysis of the microarray data revealed the RAS homologue 
RHOA as one of the genes with the most significant difference in expression between 
the groups with good and bad prognosis. The existing literature of RAS signaling and 
RHOA,[93,185-187] led us to investigate the potential of RHOA as a prognostic marker 
in Dukes’ C CRC. The significance of the expressional level differences was assessed 
using IHC on a tissue microarray, where the level of RHOA expression was measured 
in an independent set of 137 formalin-fixed paraffin-embedded tumor samples from 
Dukes’ C patients. These IHC results indicated that patients with low levels of RHOA 
protein in their tumors had a significantly worse overall (p-value = 0.03) and disease-
free (p-value = 0.01) survival compared with patients whose tumors had high levels of 
RHOA. Shorter survivals could also be observed in patients who had surgery as the 
only form of treatment and in those who, in addition, received 5-FU-based adjuvant 
chemotherapy. In agreement with these results, lymph node metastases showed 
significantly (p-value = 0.017) decreased levels of RHOA protein than the primary 
tumors, which further suggests that reduced RHOA expression could favor tumor 
spread.  
 
In the literature, RAS signaling deregulation is a common early event in CRC 
progression [93,185] and RHOA has been shown to regulate a signal transduction 
pathway that links plasma membrane receptors to the assembly of focal adhesions and 
actin stress fibers.[188] Recently it has been reported that high levels of RHOA can 
inhibit cell motility.[186,187] These results, together with the findings of this study, 
indicate that RHOA tumor expression levels can be a useful marker for predicting the 
probability of recurrence of Dukes’ C patients treated with or without 5-FU–based 
chemotherapy and could be used to identify a subset of patients with poor prognosis 
who could benefit from more aggressive treatment. 
4.2.4 Microarray profiling of colorectal carcinomas 
Collectively, the results of this study show for the first time the potential of gene-
expression profiling to predict the probability of recurrence of Dukes’ C CRC after 
surgery. These primary tumors are locally advanced and likely to form distant 
metastases. The tumors were shown to display a distinctive expression signature; high-
density oligonucleotide microarray analysis accurately distinguished patients with good 
and bad prognosis after surgery. Moreover, we showed that microarray-based genome-
wide screening for genes with different levels of expression at the messenger RNA 
level can be used to identify single prognostic markers for these patients. 
 
In the literature, previously performed studies have assessed the use of individual 
prognostic markers for CRC treated with 5-FU, such as LOH in chromosome 18q, 
tumor suppressor gene p53 and K-RAS.[175-184] While the studies of K-RAS have 
suggested a prognostic role for K-RAS with cancer progression, the status of p53 as a 
prognostic factor and a predictor of response to 5-FU chemotherapy is controversial: a 
number of studies have demonstrated that overexpression of p53 correlates with poor 
survival in IHC analyses in Dukes’ B stage CRC, but other studies have found that p53 
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does not display any independent prognostic role in early stage CRC.[189-192] As the 
currently used predictive markers have only limited value due to acquired or inherent 
drug resistance, gene expression profiling has been an active area of research that can 
potentially have major clinical implications to tailored therapies of CRC. 
 
Several groups have used gene expression profiling to study the prognosis in various 
tumor types such as leukemia,[52] breast [193] and lung cancer.[194] Studies using 
DNA microarray profiling to classify CRC patients according to prognosis have also 
appeared in the literature, and have adderessed, for example, response to 5-FU,[141] 
preoperative chemoradiotherapy [195] and recurrence of Dukes’ B CRC.[196] 
Recently, expression profiling has also been used to separate colorectal tumors 
harboring BRAF and K-RAS mutations from each other.[197] In the study by 
Mariadason et al. (2003) [141] gene expression profiling combined with leave-one-out 
cross validation was used in 30 CRC cell lines to identify panels of genes that 
correlated with sensitivity to 5-FU and camptothecin treatment. The analysis predicted 
the response more effectively than the 4 previously established determinants of the 5-
FU response: thymidylate synthase, thymidine phosphorylase, p53 and MSI status. 
Thymidylate synthase and thymidine phosphorylase are genes related to 5-FU 
metabolism, contributing to the apoptotic effect of the active compound. A study by 
Bertucci et al. (2003) demonstrated that gene expression profiling was able to separate 
Dukes’ stage D from stages A-C disease by hierarchical clustering and predict the 
likelihood of metastasis. Wang et al. (2004) used class prediction approaches in Dukes’ 
B colon cancer to identify a 23-gene signature that predicts recurrence in these patients. 
The Dukes’ B stage is a localized disease, where currently no adjuvant therapy is 
recommended. The study implicated that already at this stage, a gene expression 
signature could be identified to guide patients with a high risk of recurrence to a more 
aggressive therapy.  
 
The use of class prediction to find predictive markers for recurrence of different stages 
of CRC is a demanding task, as the expression array results have thus far been 
performed on relatively small datasets and may thus suffer from overfitting models. 
Validation of the obtained prognostic markers in independent experiments is a critical 
issue, as the variation caused by sample heterogeneity and processing needs to be 
filtered from results before clinical applications can be designed. However, as multiple 
studies have shown, prediction of prognostic markers and therapeutic targets from gene 
expression data is feasible, and the microarray technology offers a good chance to 
enhance the treatment of cancer patients. In the near future, extended studies, meta-
analyses of multiple datasets and further validation of currently predicted prognostic 
markers are likely to provide clinically usable markers for the prediction of CRC 
recurrence as well as other cancers. 
4.3 Molecular classification of serrated colorectal cancer (III) 
In this study, a genome-wide expression microarray profiling and IHC analyses of 
serrated and conventional colorectal tumors were performed to investigate the 
molecular basis of serrated CRCs. 
-49- 
4.3.1 Gene expression profiling and class prediction of the serrated CRC 
The expression data analysis of the 37 colorectal tumor samples, of which 8 were 
serrated and 29 conventional CRC, consisted of a class discovery approach and a 
functional gene enrichment analysis of 7928 genes. In the unsupervised hierarchical 
clustering the samples formed two distinct branches, with all but one of the 8 serrated 
samples clustering to one branch, and all 29 conventional CRC cases to the other, with 
a highly significant p-value of 7.8 × 10-7 (Fisher’s exact test for the distribution). None 
of the other parameters, such as sex, site, grade or stage of the tumors clustered 
together. Subsequently, a statistical analysis of the 7928 genes used in the clustering 
detected 226 differentially expressed genes between the serrated and the conventional 
CRCs (adjusted p-value < 0.05).  
 
Gene Ontology terms were used to classify the probes used in the unsupervised 
clustering into 685 biological processes, cellular components, and molecular functions. 
Functional group enrichment analysis was used to identify categories with a significant 
enrichment in the number of genes differentially expressed in tumors with serrated and 
non-serrated histology. Nine categories with a p-value < 0.01 were found, of which 5 
belonged to categories linked to morphogenesis (morphogenesis and organogenesis) 
and membrane associated genes (membrane, integral to membrane and integral to 
plasma membrane). 
 
The class prediction method described by Golub et al. [52] was applied to find a set of 
differentially expressed genes between the serrated and conventional CRCs to find 
whether the dataset could be used to create an expression-based classifier for unknown 
samples. The predictor was generated using a KNN-based method and 4413 probes 
detected in all 37 samples with a leave-one-out cross-validation procedure. This 
classifier, using 3 neighbors and the expression data of 10 genes from a set of 27 genes, 
correctly categorized all 37 tumors as serrated or non-serrated. Because of the cross-
validation procedure, a slightly different group of 10 genes was used in each prediction. 
4.3.2 Validation of the expression array results 
The expression microarray results were validated by IHC staining utilizing a training 
set (TS) and a validation set (VS) of paraffin embedded tissue blocks. The TS consisted 
of the 37 (8 serrated and 29 conventional) CRC samples that entered expression array 
analysis while the VS included a separate set of 37 serrated and 86 conventional CRCs 
from the same collections. Ephrin receptor B2 (EPHB2), patched (PTCH), hypoxia-
inducible factor 1-alpha (HIF1α), cyclin T2 (CCNT2), metastasis associated 1 (MTA1), 
and methyl-CpG binding domain protein 4 (MBD4), were chosen for further validation 
by IHC, based on microarray results, relevance of their biological function, and the 
commercial availability of the antibodies. The IHC results of EPHB2, PTCH and 
HIF1α demonstrated statistically significant associations with serrated morphology of 
the CRC on both TS and VS, with EPHB2 and PTCH showing reduced and HIF1α 
elevated levels of expression in the serrated tumors. The results of CCNT2 confirmed 
the array results on the TS, but failed to reach a significant level on the extended set of 
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samples. Both MTA and MBD4 showed differences on expression array analysis, but 
did not show correlation between cancer types in IHC. 
 
To examine possible causes of reduced EPHB2 expression the genomic DNA of the 
available 24 serrated tumors was sequenced for somatic mutations in the EPHB2 gene. 
Successful sequencing of 98% of the coding region yielded negative results. LOH was 
observed in 25% (3/12) of the serrated tumors displaying informative SNPs. Moreover, 
the EPHB2 promoter was hypermethylated in 63% (5/8) of the tumors, suggesting that 
these mechanisms could contribute to the reduced levels of EPHB2 in serrated tumors. 
 
Many clinical and pathological features in this study suggested that serrated CRCs may 
be more aggressive than conventional CRCs. Metastatic and poorly differentiated 
carcinomas were more frequent among the serrated CRCs. Patients with serrated CRC 
also tended to have worse survival curves than patients with conventional CRC with 
multiple studied parameters, as in male patients, MSS cancers and in moderately 
differentiated cancers. This trend has also been previously observed in a smaller set of 
serrated CRCs for distal and MSS serrated cancers.[109] The serrated CRCs also 
showed more variability in the WHO grade, tended to be more advanced, more 
frequently located in the proximal colon and represented a mucinous component more 
often than the conventional CRCs. 
4.3.3 Serrated colorectal tumors differ from conventional adenocarcinomas 
In this study, class discovery approach was used to investigate whether the serrated 
colorectal carcinoma is distinguishable from conventional CRC on gene expression 
level. Previously, serrated adenomas and hyperplastic polyps have been thought of as 
non-neoplastic lesions with no malignant potential.[198-200] Recently, though, 
evidence has been presented that certain types of hyperplastic polyps are linked with 
colorectal neoplasia.[104,108,109,112] The formation of serrated colorectal carcinoma 
is thought to differ from the conventional adenoma-carcinoma sequence and mutator 
pathway models, and instead follow an alternative route of colorectal carcinogenesis 
from hyperplastic polyps to serrated adenomas and adenocarcinomas,[104,201] where 
hypermethylation may play an essential role.[110,111] Other molecular features, such 
as frequent mutations in BRAF [113] and MSI,[107-109] have also been associated 
with the serrated phenotype. Currently, the serrated CRCs are diagnosed based on 
morphological differences. The recognition of serrated carcinomas as biologically 
different tumors would be of high significance, as identification of a genetic signature 
in the serrated lesions would allow a better understanding of the disease mechanisms 
and enable the development of optimal treatment methods for patients according to the 
specific tumorigenetic signatures.  
 
Gene expression profiling proved very useful in distinguishing serrated tumors as a 
distinctive subgroup of CRC, which was consistent with the hypothesis of a serrated 
neoplasia pathway proposed in the literature.[103-105] The unsupervised clustering 
together with the IHC analyses indicated that serrated and conventional CRCs display 
significant molecular differences, observed both on molecular and histopathological 
level. Interestingly, our expression microarray and IHC studies indicated that 
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upregulation of HIF1α and suppression of PTCH and EPHB2, genes involved in 
biological processes closely related to the colon cell morphology, differentiation, 
gastrointestinal tract patterning and proliferation, demonstrated statistically significant 
association to the serrated phenotype. The IHC analysis also indicated that the 
immunohistochemical staining of these proteins were useful in distinguishing serrated 
cancers from conventional cancers, and could thus be potential markers for serrated 
CRC.  
 
PTCH is a member of the Hedgehog (HH) signaling pathway, and essential for the 
maintenance of stem cells and for the patterning of the gastrointestinal tract during 
development.[202] Germline mutations in PTCH underlie the Gorlin syndrome, which 
is characterized by the early onset multiple basal cell carcinomas and increased rate of 
some other tumors such as medulloblastomas.[203,204]. This gene has also been found 
in many different sporadic tumors and thought to act as a tumor suppressor.[205]  
HIF1α activates the transcription of genes that are involved in crucial aspects of cancer 
biology, including angiogenesis, cell survival, glucose metabolism and invasion, and 
has been associated with cell proliferation in colon carcinoma.[206-208]. EPHB2 is a 
member of a receptor tyrosine kinase family that regulates several signaling pathways 
involved e.g. in cell growth and migration.[209] The gene maps to chromosome 1p36, 
which is a chromosomal region reported to be lost in 13% of hyperplastic polyps [210] 
and is also mutated in PC.[130] Recently, it has also been demonstrated to regulate the 
development and positioning of cells in the small intestine [211] and to play a critical 
role in CRC progression, [212] making it a putative tumor suppressor gene. Based on 
the study results and existing literature, these could be candidate genes involved in the 
serrated neoplasia pathway. 
 
To study the solid tumors is challenging, as the tumor biopsies generally used in the 
studies may, in addition to the tumor cells, contain cells from the surrounding tissues, 
such as endothelia, connective and muscle tissue. To minimize these problems in this 
study, the array material was screened from fresh-frozen blocks and macrodissected 
from histologically confirmed locations. Additionally, selection bias was diminished by 
using population-based cohorts. However, the likely heterogeneous nature of serrated 
adenomas and the relatively small number of biological replicates in the class discovery 
and prediction analyses of this study are prone to cause sample-wise variation and 
model overfitting, as reported in the literature by Ambroise et al. (2002) and Allison et 
al. (2006).[36,213] In this study, the class prediction results were validated using a 
“leave-one-out” method, which does enhance the confidence of the classifier, but is not 
as good as an independent validation set. In these studies (II, III) however, the accuracy 
of the expression data was independently confirmed by IHC using an independent 
sample set. This greatly increases the level of confidence in these experiments, and 
suggests that overfitting was less of a concern in these studies. 
 
Identification of sub-groups of tumors with different expression profiles is a classical 
example of the use of microarray technology in cancer research. This approach has 
been extensively demonstrated in a number of studies including colon cancer,[214] 
prostate cancer,[121] head and neck squamous cell carcinoma,[215] breast cancer [114] 
and leukemia,[52,126] to name a few. The earliest microarray-based classifications in 
CRC were published by Alon et al. (1999) and Notterman et al. (2001) [122,216] who 
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used clustering to distinguish CRC and normal tissue. Later publications by Bertucci et 
al. (2003) used unsupervised and supervised clustering to distinguish normal vs cancer 
tissues and metastatic vs non-metastatic tumors in colon cancer, which were further 
validated by IHC analyses using tissue microarray. A study by Frederiksen et al. (2003) 
[217] used KNN-based classifier to classify normal, and Dukes’ B and C samples with 
less than 20% error. Despite the obvious challenges inherent in microarry classification 
of tumors, in the literature – as in this study - it has been possible to define expression 
profiles of subset of tumors, which is an important step towards individual tumor 
profiling and tailor-made tumor therapy.  
4.4 EPHB2 and colorectal tumorigenesis (IV, V) 
In the previous study (III), expression microarray analyses indicated a decreased level 
of EPHB2 gene expression in serrated colorectal tumors, which was validated on 
protein level experiments by IHC. Our findings, together with the concurrently growing 
evidence of the role of EPHB2 in CRC tumorigenesis,[211,212] and PC [130] 
prompted us to further investigate the role of EPHB2 in colorectal tumor 
predisposition. This was done by studying molecular mechanisms responsible for the 
inactivation of the gene. 
4.4.1 EPHB2 germline variants in colorectal tumorigenesis (IV) 
The EPHB2 germline alterations were screened in a set of 101 samples consisting of 
CRC patients with either personal or family history of PC or intestinal hyperplastic 
polyposis (HPP). Overall, variants that may be associated with the disease phenotype 
were seen in 3/101 (3.0%) patients analyzed in the initial mutation screening. Two of 
the changes, I361V and R568W, were identified in Finnish CRC patients, but not in 
over 300 Finnish familial CRC or PC patients or more than 200 population-matched 
healthy controls. The third change, D861N, was observed in a UK HPP patient, but not 
in additional 40 UK HPP patients or in 200 UK healthy controls. A fourth change 
R80H, originally identified in a Finnish CRC patient, was also found in 1/106 familial 
CRC patients and in 9/281 healthy controls and was considered as a likely neutral 
polymorphism. The data from this study is compatible with the results by Oba et al. 
(2001), who found no EPHB2 germline mutations among 50 CRC patients.[218]  
 
The rarity of germline EPHB2 alterations in this and in a previous study,[218] together 
with the sequential loss of EPHB2 expression during colorectal carcinogenesis, 
suggests a limited role for EPHB2 in CRC predisposition and speaks for the more 
pronounced role for EPHB2 in tumor progression than in tumor initiation. Therefore, 
although some possibly disease associated germline EPHB2 variants do exist and may 
play a role in colorectal tumor predisposition, the observed EPHB2 inactivation in 
CRCs appears to be largely due to other mechanisms, such as promoter 
hypermethylation, LOH, and somatic mutations.[132,219] Notwithstanding, germline 
EPHB2 variants do exist and may be associated with colon tumor predisposition, but 
further studies including functional analyses are needed to confirm this. 
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4.4.2 Mechanisms of EPHB2 inactivation in colorectal tumors (V) 
EPHB2 gene contains an A9 track in exon 17 that could be a target for mutation in 
tumors with MSI. To investigate the role of the A9 repeat of EPHB2 in CRC 
tumorigenesis, we screened 24 MSI colorectal cell lines and 246 primary MSI 
colorectal tumors by direct sequencing and found that 9 of the cell lines (37.5%) and 
101 of the tumors (41%) had mutations in the A9 repeat. All of the found mutations 
changed the translational reading frame, and either added a 26–amino acid tail or 
prematurely truncated the protein. In all cases, two serine residues (S1048 and S1052) 
were lost in the mutant EPHB2. These residues have been predicted to be 
phosphorylated in the wild-type protein [220] and might thus play a role in the protein 
kinase activity. In a screened set of 29 MSI adenomas [139] we found that 20.7% of 
these adenomas (6 of 29) had a mutation in the A9 repeat of EPHB2, which was 
significantly lower than in MSI carcinomas (41%, 101 of 246; χ2 test p-value = 0.03). 
This observation was in good agreement with earlier reports showing that EPHB2 
expression was reduced or lost in colorectal carcinomas, but not in adenomas,[212] and 
further suggests that EPHB2 inactivation may be important for the transition from 
adenoma to carcinoma.  
 
Hypermethylation of cytosines located within CpG islands in the promoter of tumor 
suppressor genes is emerging as an important mechanism of gene silencing.[221] The 
proximal promoter of EPHB2 contains a CpG island spanning 1400bp and provides a 
site for aberrant methylation. The DNA methylation status of this region was 
determined in 60 MSI and 41 MSS colorectal tumor samples and in 20 MSS CRC cell 
lines with methylation specific PCR. The results showed 53.4% (54/101) of the tumors 
and 25% of the cell lines (5/20) to be hypermethylated. No differences were seen 
between the MSI and MSS tumors. The treatment of a cell line showing EPHB2 
promoter methylation with a demethylating reagent resulted in a substantial up-
regulation of EPHB2 protein levels and demonstrated that aberrant methylation can 
regulate EPHB2 expression. 
 
This study described for the first time the mechanisms of EPHB2 inactivation in 
colorectal tumors, caused by frequent mutations in repetitive sequences in exon 17 in 
MSI adenomas and carcinomas and hypermethylation of the EPHB2 promoter in the 
majority of the tumors.  
4.4.3 EPHB2 in colorectal tumorigenesis 
The Wnt signaling pathway plays a central role in the development of CRC. In the 
majority of cases the early events in tumorigenesis involve inactivation of the tumor 
suppressor gene APC and stabilization of β-catenin.[222,223] The constitutive activity 
of β-catenin/transctiption factor 4 (TCF4) –complex leads to transcription of growth 
promoting genes, which together with subsequent inactivation of tumor suppressor 
genes drive the tumorigenesis further and enable the formation of abnormal growth 
patterns. Recently, EPHB2 was demonstrated to be one of the direct transcriptional 
targets of β-catenin, and participate in the correct positioning of the cells along the 
crypt axis in the intestinal epithelium.[211] Furthermore, EPHB2 maps to a 
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chromosomal region (1p36) frequently altered in colorectal tumors [218,224,225] as 
well as in many types of cancer,[226] and was recently shown to function as a putative 
tumor suppressor gene in CRC.[212] Recent findings have also demonstrated that 
silencing of EPHB2 correlates inversely, and is a strong indicator of poor overall 
survival in CRC.[227,228] The evidence present thus far suggests that EPHB2 is a new 
tumor suppressor gene in CRC with a role in tumor progression. 
 
These studies demonstrate the benefits of integrated use of microarray technology and 
data mining together with other research methods. When connected to the existing 
literature and concurrently published studies, individual findings such as EPHB2 in this 
study begin to have functional significance and thus become interesting targets for 
further studies. In general, microarray data analysis often requires extensive data 
mining, and conclusive evidence of the involvement of a gene in carcinogenesis is 
achieved only after validation of the results by functional testing. 
4.5 Future prospects of array technologies   
The future of microarray research in cancer is going towards a systems biology view, 
where the aim is to change focus from individual genes to pathways and more complex 
signalling networks in the cells. These kinds of integrative methods, such as meta-
analyses of multiple datasets and studies of transcription factor networks have already 
been published and reviewed in the literature,[229] but require input from other high-
throughput molecular approaches such as SNP arrays, array comparative genomic 
hybridization and proteomic solutions to become useful and more informative. 
However, retrospectively, it is astounding to note that microarray technology has been 
around for only a decade. When looking at the annually increasing rate of publications 
related to microarrays, it can be stated that biomedical sciences are evolving at an 
unprecedented pace. 
 
Array technologies, together with bioinformatics methods related to it, have founded a 
novel platform for cancer research. Chip-based experiments are becoming a standard 
practise in basic research, both in studies of tumor biology and prognostic markers for 
the disease. Applications based on targeted therapies are also making their way to the 
mainstream clinical practise, as the expression of specific target genes in tumors and 
means to interfere with them are discovered and understood. When the prices of 
microarrays become comparable to currently utilized diagnostic tests and the target 
preparation and data analysis of the arrays have been standardized to meet the quality 
expected from medical treatment methods, gene expression profiling may eventually 
allow a personalized treatment of cancer by tailoring therapies to the biologically active 
pathways in each patient’s tumor. 
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5 Conclusions 
Molecular biology and the technology that supports it have lately advanced in ways that 
were inconceivable a decade earlier. The development of DNA microarray technology 
together with the mapping of the genomic sequence has made it possible to analyze the 
expression of the total human genome in a single experiment and perform extensive 
data mining at the subcellular level. This has given the scientists valuable insight into 
various diseases, such as human cancer, and increasing interest exists in changing the 
emphasis of tumor classification from morphologic to molecular. 
 
In Publication I, a genome-wide expression profiling was performed on yeast strains 
with fumarase mutations that in human predispose to the HLRCC syndrome. The 
results showed that the mutant and knockout strains have similar expression profiles. 
While the fumarase mRNA and protein expression was at comparable levels between 
the mutant and WT strains, functional studies showed that the enzyme activity in the 
mutant strains was only a fraction of the activity seen in the WT strains. This residual 
activity was nonetheless crucial and sufficient to support normal growth phenotype. 
This supports the hypothesis that modifier gene(s) display a major role in determining 
tumor types in families segregating FH mutations. In addition, the study demonstrated 
that while microarray experiments on model organisms were useful in providing data of 
gene expression changes for HLRCC studies, functional analyses were essential to 
complement and understand the significance of the results at the cellular level. 
 
In Publication II, expression microarrays were used to distinguish surgically cured 
Dukes’ C CRC patients from those at high risk of recurrence. Unsupervised clustering 
and class prediction methods were able to identify groups of patients with significantly 
different survival and outperformed previously reported genetic markers of prognosis. 
One of the most differentially expressed genes in the experiment, RHOA, was further 
analyzed as a potential prognostic marker by using IHC and tissue microarray. The 
study showed that gene expression profiling of surgical samples can predict the 
recurrence of Dukes’ C patients and could perhaps be used to guide decisions 
concerning the clinical management of these patients. 
 
In Publication III, gene expression profiling was used for molecular classification of the 
serrated CRCs. Unsupervised clustering showed that serrated carcinomas appear to be a 
subclass of CRC with distinct molecular basis. The study provides a platform to 
understand the molecular basis of serrated CRC and in long term may contribute to the 
development of specific treatment options for this tumor type. 
 
In Publications IV and V, EPHB2 - a key target gene revealed by the expression data 
analysis in Publication III - was further studied in colon tumors and normal tissue to 
find out about its relevance to CRC tumorigenesis. These studies showed that EPHB2 
germline variations exist and may be associated with colon tumor predisposition. 
However, rarity of these events suggests a limited role for them and the mechanisms of 
inactivation appear to be largely due to frequent frameshift mutations as observed in 
MSI colorectal tumors and aberrant methylation of the regulatory sequences of EPHB2. 
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In conclusion, in this dissertation expression microarray technology and supporting 
technologies were used in studies of hereditary renal cell cancer and CRC. While the 
expression arrays were limited to detecting aberrant gene expression levels, and did not 
capture the changes at translational level, they still offered a very powerful platform to 
study genetic interactions and molecular mechanisms on a genome-wide level. Careful 
designing, sample preparation and use of sufficient amount of biological replicates in 
the experiments were found to be crucial elements. The usefulness of the technology 
was greatly enhanced by combined use of other research methods, such as functional 
studies, which enabled focusing of the analyses and provided better insight into the 
complex regulation of gene and protein networks involved in cancer. Although 
presently the expression array technology is primarily used in basic research, previous 
studies as well as results obtained from this dissertation indicate that clinical 
applications are foreseeable and slowly emerging, and can benefit the treatment of 
cancer in form of individually tailored therapies based on the molecular signature of a 
patient’s tumor. 
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